Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment

Kasturee Chakraborty1,*, Archana Tripathi1,*, Sukumar Mishra1,*, Argha Mario Mallick1,* and Rituparna Sinha Roy1,2,3

1Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India; 2Centre for Advanced Functional Materials, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India; 3Centre for Climate and Environmental Studies, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, India

Correspondence: Kasturee Chakraborty (kastuchak@gmail.com) or Argha Mario Mallick (pspmallick@gmail.com) or Rituparna Sinha Roy (rituparna@iiserkol.ac.in)

Nanotherapy has emerged as an improved anticancer therapeutic strategy to circumvent the harmful side effects of chemotherapy. It has been proven to be beneficial to offer multiple advantages, including their capacity to carry different therapeutic agents, longer circulation time and increased therapeutic index with reduced toxicity. Over time, nanotherapy evolved in terms of their designing strategies like geometry, size, composition or chemistry to circumvent the biological barriers. Multifunctional nanoscale materials are widely used as molecular transporter for delivering therapeutics and imaging agents. Nanomedicine involving multi-component chemotherapeutic drug-based combination therapy has been found to be an improved promising approach to increase the efficacy of cancer treatment. Next-generation nanomedicine has also utilized and combined immunotherapy to increase its therapeutic efficacy. It helps in targeting tumor immune response sparing the healthy systemic immune function. In this review, we have summarized the progress of nanotechnology in terms of nanoparticle designing and targeting cancer. We have also discussed its further applications in combination therapy and cancer immunotherapy. Integrating patient-specific proteomics and biomarker based information and harnessing clinically safe nanotechnology, the development of precision nanomedicine could revolutionize the effective cancer therapy.

Introduction
Cancer remains the most fatal and life-threatening disease worldwide, causing an estimated 19.3 million new cases and 10.0 million deaths in 2020 [1]. Current therapeutic approaches are not found to completely cure the advanced cancer having distant organ metastases. Treatment of cancer follows several approaches, including locoregional (surgery and radiation therapy), chemotherapy, endocrine (hormone) therapy, targeted therapy, etc. Such therapeutic approaches also possess certain disadvantages such as fatigue, numbness, nail changes, hair loss, loss of appetite, mouth sores, nausea, weight changes, vomiting, diarrhoea, heart damage, etc [2–6]. In spite of its huge potential, chemotherapy remains disadvantageous in having off-target side effects and non-specific delivery [7]. Nanotechnology has become a promising approach to overcome this limitation. The nano-sized materials provide opportunities for their use in diagnosing, monitoring, controlling, preventing and treating diseases [8]. The concept of nanoparticles was first adapted by Nobel laureate Richard P. Feynman in his famous lecture entitled “There’s plenty of room at the bottom” in December 1959 [9]. Nanotherapy is the therapeutic strategy harboring nanoparticles ranging from 10 to 100 nm for intravenous delivery [10,11]. Nanoparticles below 10 nm diameter are prone to renal clearance [11]. Widely used examples of nanoparticles having anticancer efficacy are Doxil, a liposomal formulation of Doxorubicin and Abraxane, an albumin-bound nanoparticle of paclitaxel [12]. These drugs also received approval from U.S. Food and Drug Administration (FDA). Apart from that, several other nanotechnology platforms like organic, inorganic and organometallic nanoparticles have also
Figure 1. Overview of the basis of multifunctional cancer nanotherapy and its potential applications
The figure describes the targeting strategies involved in nanotherapy, the composition of nanoparticles, types of cargo and its further applications in combination therapies.

been used over the past two decades for therapeutic, diagnostic and theranostic purposes [13]. Nanoparticles can be easily custom-tailored and advantageous in having the following features: (1) carry a high payload of biologically active drug [11,14,15], (2) protects the drug from degradation, (3) contain large surface area to accommodate multiple targeting ligands (4) larger surface to interact with multiple types of drug molecules, (5) controlled release profile of drug and (6) potential to bypass multidrug resistant mechanism [11,16,17].

Nanotechnology also undergoes several barriers that hinder its successful translation into the clinic. Various biological barriers limit the functionality of the nanoparticles and their clinical outcome. Nanoparticles get easily phagocytosed and degraded by the macrophages of the liver, spleen, lungs, lymph nodes and skin [13]. According to recent statistics, 0.7% of the total injected dose can get targeted to tumor. The primary reason for this failure is the formation of protein corona (proteins adsorbed on the nanoparticle from plasma and/or intracellular fluid) around nanoparticles and their subsequent opsonization (the process where opsonins or extracellular proteins bind to the surface of the nanoparticles, causing the degradation of nanoparticles by phagocytes) and eventual phagocytosis [10,13]. High encapsulation efficiency of a drug does not always lead to high therapeutic potential. Again, hydrophobic drugs which precipitate over time also do not show significant efficacy [10]. Therefore, designing a potent yet stable nanoparticle has always been challenging. In the following section, we will focus on the strategies acquired by the researchers in designing effective nanoparticles to aid anticancer therapy and we will also describe the progress made so far with nanotherapy.

By designing suitable combinatorial nanotherapeutics, one can achieve targeted delivery, reduce side effects of free drugs, delay in developing drug resistance and accomplish synergistic drug interactions at low doses [18]. Oncogenic signaling pathways can also be targeted using nanoparticles to selectively target the tumor cells without causing systemic toxicity. Moreover, nanomedicine mediated anti-angiogenic drug delivery makes them more reachable towards tumor vasculature. Furthermore, nanoparticles potentiate the gene therapy to introduce therapeutic nucleic acids into target cells to achieve curative response in cancer patients [19]. Recently, nanotherapy has also been used to deliver immunotherapeutic drugs in combination with conventional therapeutic modalities (e.g., chemotherapy, RNAi therapy, photothermal, photodynamic and radiotherapy) to increase anti-tumor efficacy [20]. Minimally invasive photothermal therapy allows killing of cancer cells by heat generated upon their exposure to the near infrared
Figure 2. Targeting strategies of nanoparticles

Figure illustrating (A) the passive targeting (enhanced permeability and retention effect or EPR effect) and (B) the active targeting into a tumor. In passive targeting, nanoparticles extravasate through the leaky blood vessels of tumor vasculature having gap sizes of 100 nm to 2 μm. Due to poor lymphatic drainage, nanoparticles home at the tumor site. In active targeting, targeting ligands are attached to the nanoparticles that specifically target cancer’s overexpressed receptors. The optimal size range to perform the EPR effect is 20–200 nm.

(NIR) light [20]. Similarly, photodynamic therapy utilizes photosensitizers which upon exposure to light releases reactive oxygen species and induce cellular toxicity toward tumors [20]. Radiotherapy induced radiation damage of cancer cells is widely used in cancer treatment, which allows curative treatment of 40% patients out of >50% of the patients with cancer treated by radiotherapy [20,21]. Cancer immunotherapy has gained tremendous attention for providing long-term treatment in cancer, as it facilitates immunological memory induced delay in cancer remission. One of the key challenges of implementing immunotherapy is off-target responses. Nanotherapy has potential to overcome this challenge by delivering these immunotherapeutic drugs to desired target sites [22]. In this review, we have discussed the potential applications and the strength of nanotherapy by combining therapies like chemotherapy, gene therapy and immunotherapy. The central theme of this review is on engineering multifunctional cancer nanotherapy as described in Figure 1.

Nanoparticle designing

Engineering multifunctional nanoparticle or precision nanomedicine still remains challenging. The primary aim of nanoparticle design is to transport therapeutic drugs and imaging agents. Such cargos are loaded on to nanoparticles either by chemical conjugation or by encapsulation [7]. Researchers found that the encapsulation technique remains more effective for clinical translation of a low potency drug than chemical conjugation. In order to produce efficacy, the drug should comprise at least 10% (wt/wt) of the entire nanoparticle composition [13]. While designing nanoparticles, certain criteria are needed to be taken into consideration, such as stability, pharmacological reasonability, pathophysiological suitability, etc [13]. Current development of cancer nanomedicine has provided answers to problems like (1) prolonged blood circulation to improve stability and bioavailability, (2) adequate tumor accumulation and (3) controlled drug release and uptake by tumor cells having a release profile for specific targeting [16,17].

Prolonged blood circulation to improve bioavailability

Proteins present in biological fluids get adsorbed in the nanoparticles when administered. Such nanoparticle-protein complexes get easily recognized by macrophages and phagocytosed [10,23,24]. To overcome this difficulty, poly(ethylene glycol) (PEG) is often used to form a hydrophilic “stealth” [25]. PEGylation promotes solubilization of the nanoparticles, prevents opsonization and increases the half-life of the drug in the blood stream [26]. Doxil (liposomal doxorubicin) is a commonly used PEGylated nanoparticle. It shows ~100 times longer half-life compared with free doxorubicin in circulation [27]. Current research has utilized nanotechnology to increase the solubility of potent but poorly soluble drugs such as cyclosporine, paclitaxel, amphotericin B, etc [28].

© 2022 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Figure 3. Different types of linkages formed due to various chemical conjugation reactions for active targeting

Stability of the linkages under physiological conditions (pH 7.4): Hydrazide-aldehyde conjugation (acid-labile), amide bond (stable), thiol-thiol conjugation (cleaved under reducing condition), gold-thiol conjugation (stable), thiol/maleimide conjugation (stable), azide/alkyne conjugation (stable) and streptavidin-biotin conjugation (stable).

Adequate tumor accumulation

Nanoparticles possess unique properties due to their small size termed as “enhanced permeability and retention effect” (EPR effect) (Figure 2A) [29,30]. Harboring this phenomenon, nanoparticles extravasate through the leaky blood vessels (inter endothelial gaps as large as 500 nm) of the tumor vasculature and preferably accumulate at the tumor site. Due to poor lymphatic drainage, they retain at the tumor site. This phenomenon is also termed “passive targeting” (Figure 2A). Nanotherapeutics used for passive targeting are listed in Tables 1 and 11. However, targeting nanoparticles to the tumor tissue does not always remain successful due to variable vessel permeability [7].

In order to circumvent these barriers, researchers have taken advantage of conjugating tumor-targeting ligands to the nanoparticle surface resulting in “active targeting” (Figure 2B) [7,41]. Binding of ligand to exposed cell surface results in “receptor-mediated endocytosis”. However, receptor density plays a pivotal role in such targeting. Commonly used targeting agents are proteins (antibody and its fragments), ligands of the up-regulated receptors (peptides, carbohydrates and other small molecules) and nucleic acid aptamers [11]. Nanotherapeutics used for active targeting under clinical trial are mentioned in Tables 2 and 11. Peptides have been widely used as receptor targeting moieties for active targeting. Table 3 enlists an elaborate list of peptide-based targeting ligands which have already been reported by Gray and Brown [42].
### Table 1 Nanotherapeutics used for passive targeting

| Name          | Formulation                                      | Diameter (nm) | Comments                                                                 | Ref.            |
|---------------|--------------------------------------------------|---------------|---------------------------------------------------------------------------|-----------------|
| SP1049C       | Pluronic micelle+DOX                             | 22–27         | Micelle nanoparticle                                                      | [11,31]         |
| NK911         | PEF-Asp micelle + DOX                           | 40            | Micelle nanoparticle                                                      | [11,31]         |
| Doxil         | PEG-liposome +DOX                               | 80–90         | PEGylated liposome nanoparticle with a more extended time of circulation, less toxicity, prevents phagocytosis | [11,31]         |
| Genexol-Pm    | PEG- poly-lactic acid (PLA) micelle+paclitaxel   | 20–50         | Micelle nanoparticle                                                      | [11,31]         |
| Abraxane      | Albumin+paclitaxel                              | 120 (May dissolve upon exposure to blood) | Albumin nanoparticle                                                     | [11,32]         |
| XYOTAX        | Poly-l-glutamic acid (PG) + paclitaxel           | Not reported  | Polymer nanoparticle                                                      | [11,33]         |
| LE-SN-38      | Liposome+SN-38                                  | Not reported  | Liposome nanoparticle                                                      | [11,34]         |
| CT-2106       | PG+camptothecin                                 | Not reported  | Polymer nanoparticle                                                      | [11,35]         |
| IT-101        | Cyclodextrin-containing polymer+camptothecin     | 30–40         | Polymer nanoparticle with extended circulation times                      | [11,36]         |
| CCN           | Candesartan clevekt loaded nanoemulsion          | 35.5 ± 5.9    | Nanoemulsion formulation with increased aqueous solubility               | [37]            |
| NCS-DOX       | Nanocapsules with oily selol core and a shell of poly(methyl vinyl ether-co-maleic anhydride) + DOX | 170           | Polymethyl vinyl ether-co-maleic anhydride nanocapsules facilitate the co-delivery of drugs | [38]            |
| NCI/NCa       | (DNase)-degradable DNA nanoclew embedded with an acid-responsive DNase I nanocapsule (NCa) + DOX | 150–180       | DNA-based nanoparticle                                                    | [39]            |
| MWNTs/DOX/TC  | TAT Chitosan functionalized multi walled carbon nanotube (MWCNT) + DOX | 200–300       | Multiwalled carbon nanotube-based nanosystem                             | [40]            |

### Table 2 Antibody and peptide-based nanotherapeutics used for active targeting in the clinical trial

| Name                                      | Targeting agent                                           | Therapeutic agent | Status           | Comments                                                                 | Ref.            |
|-------------------------------------------|-----------------------------------------------------------|-------------------|------------------|--------------------------------------------------------------------------|-----------------|
| Gemtuzumab ozogamicin (Mylotarg)          | Humanized anti-CD33 antibody                              | Calicheamicin     | FDA approved     | Antibody-drug conjugate (ADC)                                            | [11,43]         |
| Denileukin diftitox (Ontak)               | Interleukin 2 (IL-2)                                      | Diphtheria toxin fragment | FDA approved     | Recombinant fusion protein of IL-2 attached to diphtheria toxin fragments | [11,44]         |
| Ibritumomab tiuxetan (Zevalin)           | Mouse anti-CD20 antibody 90Yttrium                        | FDA approved      | Antibody-radioactive element conjugate                                   | [11,45]         |
| Tositumomab (Bexxar)                     | Mouse anti-CD20 antibody 131Iodine                        | FDA approved      | Antibody-radioactive element conjugate                                   | [11,45]         |
| FCE28069 (Pk2)                           | Galactose                                                 | Doxorubicin       | Phase I clinical trial (stopped)                                         | [11,46]         |
| MCC-465                                   | F(ab)′2 fragment of human antibody GAH                    | Doxorubicin       | Phase I clinical trial                                                  | [11,47]         |
| MBP-426                                   | Transferrin                                               | Oxaliplatin       | Phase I clinical trial                                                  | [11,48]         |
| SGT-53                                    | Antibody fragment to transferrin receptor                 | Plasmid DNA with p53 gene | Phase II clinical trial                                                 | [11,49]         |
| CALAA-01                                  | Transferrin                                               | Small interfering RNA | Phase I clinical trial                                                  | [11,50]         |
| BIND-014                                  | Prostate-specific membrane antigen (PSMA)-targeted peptide (GDHSPFT, SHFSVGS and EVPRLSLLAVFL) | Docetaxel         | Phase II clinical trial                                                  | [51, 52]        |
Figure 4. Structural components of multifunctional cancer nanomedicine

Commonly used therapeutic agents are chemotherapeutic drugs, RNAi therapeutics, and imaging agents include MRI contrast agents, radionuclides, fluorescent probes, etc. Therapeutic agents can either be covalently conjugated or non-covalently encapsulated. Attaching imaging probes with nanoparticles containing therapeutic agents make it a theranostic platform (this image was drawn based on the information provided in Chou et al. 2011 [70], Figure 1).

Conjugation of ligands with the nanoparticles is mediated via covalent or non-covalent chemical conjugation. However, non-covalent conjugation often leads to weak bonding making it less efficacious. Covalent coupling is commonly achieved with the conjugations of the following groups (1) hydrazide-aldehyde, (2) carboxylic acid-primary amine, (3) thiol-thiol, (4) gold-thiol, (5) maleimide and thiol and (6) azide-alkyne. Different types of linkages formed due to various chemical conjugation reactions are described in Figure 3 [60,61].

Size, shape and surface modification also remain essential to achieve effective tumor targeting (Figure 4). In order to specifically target the tumor, nanoparticles must first travel in circulation without being engulfed by macrophages [62]. Nanoparticles having a diameter of \(\sim 5\) nm undergo rapid renal clearance, whereas nanoparticles of 50–100 nm diameter mostly accumulate in the liver. Larger particles \(> 2000\) nm in diameter tend to accumulate in the spleen. It has been found that nanoparticles having a diameter of 100–200 nm can escape filtration by the liver and spleen (Figure 5) [10]. Researchers observed that nanoparticles of size ranges 30-50 nm diameter showed maximum cellular internalization ability [63]. Studies have also shown that the size of nanoparticles is also dependent on tumor maturity. Reports suggest that with increasing particle size, the area of permeation within tumors become smaller [64]. Gold nanoparticles with 15–45 nm diameter have been found to accumulate in tumors of 0.5-1 cm\(^3\) volume or above [65]. Recent findings suggest that the shape of the nanoparticles also determines the cellular uptake [66]. Several nanostructures like 2D polygonal shape, 3D polygonal shape, rod, snowflakes, flowers, thorns, hemispheres, cones, filaments, etc., have been designed to study their efficacies [62]. Recent studies have revealed that oblate shape is favoured in circulation [62]. Mitragotri and co-workers have modified a solid polystyrene microparticle into a red
Figure 5. Biodistribution of nanoparticles

Nanoparticles having different (A) size, (B) shape, (C) surface charge and their biodistribution in different organs. This figure will guide us for designing organ-specific delivery of nanoparticles (this image was drawn based on the information provided in Blanco et al. 2015 [10], Figure 5).

blood cell (RBC) shaped particle using layer-by-layer (LbL) self-assembly technique. The nanoparticles were synthesized using PLGA, which can be used as a carrier for drug and imaging agents [67]. Additionally, RBC-derived cell membrane and a hybrid membrane having membrane from RBC and cancer cell line were used for delivering chemotherapeutic drugs and such methodologies can be explored for designing personalized nanomedicine [68,69]. Surface charge of the nanoparticles also plays a significant role in nanoparticle internalization (Figure 4). Current studies have demonstrated that nanoparticles having a size range of 50–100 nm carrying a very slight positive charge favour the penetration in large tumors [11].

A transient increase in blood pressure during systemic administration also causes increased tumor-specific nanoscale drug delivery. For \textit{in vivo} delivery, near the wall margination is favored that interacts with the tumor vasculature bed. RBCs tend to travel in the middle of the blood flow, creating a “cell-free layer”. Spherical nanoparticles follow the bloodstream whereas, rod-shaped nanoparticles undergo a lateral drift due to variable drag forces and torques. Nanorods show a 7-fold higher accumulation at the vessel lining than nanospheres. Again, discs marginate two times higher than rods. Particles are deposited at a higher rate at the site of the vessel bifurcation [62]. Additionally, the “multivalency” of a nanoparticle can be harnessed to enhance the binding affinity or avidity of ligand to receptor interaction [7]. It has been found that oblong-shaped nanoparticles are more helpful in forming more multivalent interactions compared to spherical nanoparticles (Figure 6) [62]. The cellular internalization process also depends...
Figure 6. Multivalent interaction of nanoparticles (having different shapes) with cell surface receptors

(A) Role of the shape of nanoparticles on multivalent interaction with cell surface receptors. Compared with nanospheres, oblong-shaped nanoparticles can form more multivalent interactions, which is required for vascular targeting (this image was drawn on the basis of information provided in Blanco et al., 2015 [10], Figure 3).

(B) Role of contact angle of nanoparticles in intracellular internalization. Rod-shaped nanoparticles tend to internalize faster when it is present perpendicularly on the cell membrane. Due to the symmetry of the spherical nanoparticles, they do not prefer any specific contact angle (This image was drawn on the basis of information provided in Toy et al., 2014 [62], Figure 2).

Controlled drug release

An ideal drug delivery platform should possess the ability to target and control the drug release, which facilitates sustained release of drugs [72]. Drug delivery often renders toxicity and side effects. These hurdles can be overcome by controlled drug release. This feature also leads to a high therapeutic index for the conjugated drug molecule. The binding of the drugs to the nanoparticles is achieved by adsorption, absorption, entrapment (the process of incorporation of a drug into a matrix) and covalent binding. The release of the drug molecules is decided on the basis of their solubility, desorption, diffusion through nanoparticles matrix, degradation of nanoparticle matrix and combination of such phenomena [73,74]. In many of such formulations, a phenomenon called “burst release” is often observed. A large bolus of drug is immediately released before it reaches to a stable profile. Researchers found that low molecular weight drugs are prone to exhibit burst release profile. Burst release may often lead to local or systemic toxicity, short half-life of drugs in vivo and shortened release profile [72]. Researchers have often modified the nanoparticles to get over this difficulty. Le and co-workers have used chitosan to modify PLGA nanoparticles carrying paclitaxel...
Table 3 Receptor targeting peptide sequences

| Receptors                                      | Cell line              | Peptide sequence                  | Ref. |
|------------------------------------------------|------------------------|-----------------------------------|------|
| Met                                            | MDA-MB-231             | YLFSVHWPPLKA                       | [42] |
| HER2/ErbB2                                     | MDA-MB-231             | KCCYSL                             | [42] |
| Transferin                                      | MDA-MB-231, HeLa       | THRPPMWSPW                   | [53] |
| αvβ3                                           | MDA-MB-231, HUVEC      | CDCRGDCFC                         | [42] |
| EGFR                                           | MDA-MB-468, MDA-MB-231| YHWYGYPQNV                        | [42] |
| IL-6 receptor                                   | B9                     | LSLITRL                           | [42] |
| Somatostatin receptor Type 2 (SSTR2)           | Breast, ovarian and cervical cancer cell lines | fc[CFwKTC]T(ol) (Octreotide) (f : 1HPhenylalanine, w : 1HTrp, c : cyclic) | [54,55] |
| Ghrelin receptor (GnRH-R)                      | Breast, lung, ovarian and prostate cancer cell lines | pGlu-HWSYkLRPG-NH2 (pGlu : Pyroglutamic acid, k : 1Hys) | [54] |
| Bombesin/Bn receptors                           | Prostate, breast, pancreas and small cell lung cancer cell line | yQWAV-βAla-HF-Nle-NH2 (y : 1HTrp, Nle : Nleucine, βAla : 1H-Ala) | [54,56] |
| Vasoactive intestinal peptide receptors (VIP receptors) | Breast, colon and endocrine cancer tumor cells | HSDAVFTDNYTRLFKQMAVLYNSILN-NH2 | [54] |
| Neurotensin receptor 1 (NTSR1)                 | Breast, colon and pancreatic cancer cells | RRPYIL                             | [54,57] |
| CCK2R                                           | Liver, thyroid and pancreatic cancer cells | eAYGWMDF-NH2 (e : 1HGlutamic acid) | [54] |
| MC1R                                            | Melanoma cells         | Ac-Nle-DHRWGK-NH2 (Ac : Acetyl, f : 1HPhenylalanine) | [54,58] |
| Human Y1 receptor (hY1R)                       | Ewing sarcoma and breast cancer cell lines | YPSKPDPFGEDAPALRYYSLRHYNLTPRYP-NH2 | [54] |
| N-cadherin                                      | HUVEC                  | SWTLYTPSQGSK                      | [42] |
| Carbonic anhydrase IX                           | Renal cell carcinoma cell lines | YNTNHVPLSPKY                     | [42,59] |

Figure 7. Illustration of size (diameter) dependent nanostructure internalization due to membrane wrapping
This figure indicates that 40–50 nm gold nanostructures show optimum cellular uptake activity due to membrane wrapping. Smaller nanoparticles readily dissociate from receptors before being engulfed by the membrane, whereas extremely large nanoparticles fail to cause membrane wrapping (this figure was prepared based on the information provided in Jiang et al., 2008 [71], Figure 3A).
Receptor tyrosine kinase (RTK)

Ras/MAPK pathway

BMS-214662, L-778123, SCH-66336, R11577, AZD3409

GTP

RAS

GRB2

SOS

GDP

PI3K/Akt pathway

PHA 665752, Imatinib, Sunitinib, Sorafenib

*PI3K*

PI(4,5)P2

PI(3,4,5)P3

Akt

mTOR

Rapamycin, CCI-779, RAD001, AP23573

LY294002, wortmannin

RTKs

EGFR, PDGFR, VEGFR, MET, FGFR, AXL, IGFR, ROS1

Figure 8. Oncogenic receptor tyrosine kinase pathway with its downstream signaling pathways and small molecule inhibitors targeting different proteins of the network

Receptor tyrosine kinase (RTK) plays a significant role in cellular proliferation. MAPK and PI3K-AKT-mTOR pathways are two key downstream pathways of RTK. Targeting these pathways has remained a successful approach to cause the antitumor effect. Small molecule inhibitors have been widely used for targeting different components of such pathways. Several small molecule inhibitors targeting different proteins of RTK signaling pathways are depicted in this diagram.

and monitored the drug release profile. They found that modification of PLGA nanoparticles with chitosan led to reduced burst release of drug [75]. Again, designed nanoparticles that are prone to transcytosis (the vesicular transport of macromolecules from one side of a cell to the other) possess the potential to reach tumor cells and show efficient anticancer efficacy [76].

Nanotechnology has made advancements in mediating anticancer therapy and imaging at the tumor microenvironment. Several synthetic and natural nanoparticles have been used currently. These include polymeric conjugates and polymeric nanoparticles ((N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, Poly(lactic co-glycolic acid) (PLGA) copolymers, etc.; liposomes and micelles; synthetic organic nanoparticles such as dendrimers; carbon-based nanostructures such as carbon nanotubes (CNTs) and polyhydroxylated/PEGylated fullerenes; inorganic nanoparticles of gold, silver, and iron oxide; quantum dots (QDs); viral capsids and ferritin, etc [7]. Liposomes are spherical vesicles comprising of one or more lipid bilayers, especially phospholipids. Liposomes have been widely used as a drug delivery vehicle. These increase the drug’s efficacy and therapeutic index by protecting the drug from the external environment. Dendrimers are radially symmetric branched polymeric nanoparticles. They possess the properties like poly valency, self-assembly, chemical stability, low toxicity and solubility. Dendrimers have been widely utilized to deliver anticancer drugs. Polymeric nanoparticles contain random or block co-polymers. These are colloidal particles having a size range of 1 to 1000 nm. Drug delivery has been widely performed using polymeric nanoparticles, either by encapsulation or chemical conjugation of drugs [18].

The delivery of chemotherapeutic drugs like cisplatin has been rigorously manipulated with nanotherapy to overcome their toxicity. Sengupta and co-workers have designed a novel cisplatin nanoparticle by harnessing PEG-functionalized poly-isobutylene-maleic acid (PEG-PIMA) co-polymer. Cisplatin is released in a pH-dependent manner and shows improved antitumor efficacy both in vitro and in vivo with limited nephrotoxicity [77]. They have also engineered another novel polymer glucosamine-functionalized PIMA to complex with platinum at a unique platinum to polymer ratio. Such nanoparticles also exhibit improved efficacy against breast and lung cancer with reduced systemic and nephrotoxicity [78]. Sengupta et al. have also designed cholesterol-tethered platinum II-based supramolecular nanoparticle with increased efficacy and reduced toxicity [79]. Prolonged use of cisplatin...
leads to nephrotoxicity. In order to overcome this limitation, other next-generation platinum-based drugs have been developed. Carboplatin (cis-diamino-(1,1-cyclobutandicarboxylate)platinum(II)) has been used recently, but it shows a cross-resistance with cisplatin. Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N′]-oxalatoplatinum(II)) does not show such cross-resistance with cisplatin and is also highly soluble in water. Moreover, trans-1,2-diaminocyclohexane (DACH) ring of oxaliplatin adduct fills the major groove of DNA more efficiently than cisplatin. Scientists have derivatized the monomeric units of a PIMA copolymer with glucosamine, which chelates DACH platinum(II) and releases DACH-platinum in a sustained pH-dependent manner with reduced systemic toxicity and minimal kidney accumulation [80]. Kulkarni et al. also designed a computational algorithm to develop nanoscale supramolecular structures for cancer treatment [81].

Nanotechnologies have also been currently used for genetic treatments by nanoparticle-mediated delivery of RNAi therapeutics [10]. The primary challenge of RNAi-based therapeutics for its successful translation to clinics is the instability of RNA molecules, their rapid degradation in presence of nuclease and poor cellular uptake because of its highly anionic nature [82]. Genetic material, such as antisense oligonucleotides, mRNAs and siRNAs, and in the specific case of plasmid DNA have been used to achieve gene therapy via nanoparticles.

Peptides have been used for targeted delivery of diagnostics and chemotherapeutic agents for anticancer therapy. Peptides remain advantageous over other nanotherapeutics in terms of their self-assembling property, easy synthesis, structural manipulation to achieve protease stability, functionalization property, conjugation to the cell surface receptors and maximum therapeutic efficacy of cargo. Peptides show minimal toxicity, improved biodegradability, rapid renal clearance, and remain stable at physiological conditions. Anticancer agents like paclitaxel/docetaxel, doxorubicin, curcumin, fluorouracil have been successfully loaded on to self-assembled peptides and evaluated for their preclinical and clinical status [83]. Peptides have also been used as a potential molecular transporter based nanosystem to deliver RNAi therapeutics like siRNA [84–86].

Table 4 enlists cancer therapeutics that either have received FDA approval or are currently undergoing clinical
Table 4 Nanomaterials in clinical use

| Nanomaterial | Trade name | Composition | Application | Manufacturer | Current status | Adverse effects |
|--------------|------------|-------------|-------------|--------------|---------------|----------------|
| **Metallic** |            |             |             |              |               |                |
| Iron oxide   | NanoTherm  | Iron oxide NP conjugate with surface ligand aminosilane | Prostate cancer | MagForce | Phase 2b clinical trial | Acute urinary retention |
| Feraheme®;   |            | Iron oxide nanoparticles (coated with polyglucose sorbitol carboxymethylether). | Imaging agent for triple-negative breast cancer, head and neck cancer, non-small cell lung cancer etc. | AMAG Pharmaceuticals, Inc. | Phase 3 clinical trial | Constipation, fluid retention in the legs, feet, arms or hands, headache, nausea |
| **Gold**     | Aurimmune | Tumor necrosis factor (TNF)-gold nanoparticle | Cancer therapy (various cancer types) | Cytimmune Sciences | Phase 1 clinical trial | Fever |
|             | Aurolase   | Silica-gold nanoshells coated with PEG | Thermal ablation of solid tumors: head/neck cancer, primary and/or metastatic lung tumors | Nanospectra | Pilot study | Inflammation |
| **Organic**  |            |             |             |              |               |                |
| Protein      | Abraxane   | Albumin-bound Paclitaxel for Injectable Suspension | Cancer therapy (breast) | Abraxis Bioscience | FDA approved | Cytopenia |
| Liposome     | Doxil/Caelyx | Liposomal Doxorubicin | Cancer therapy (acute lymphoblastic leukemia) | Ortho Biotech | FDA approved | Hand-foot syndrome, stomatitis |
| Polymer      | Oncaspar   | Pegylated form of L-asparaginase | Cancer therapy (various cancer types) | Rhône-Poulenc Rorer | Phase 2 clinical trial | Urticaria, rash |
| CALAA-01     |            | Formulation of siRNA that consists of a CD-polyacrylamide, adamantane (AD)-PEG (MW of 5000) conjugate and AD-PEG-transferrin as the targeting ligand, | Cancer therapy (various cancer types) | Calando | Phase 2 clinical trial | Mild renal toxicity |
| Micelle      | Genexol-PM | Paclitaxel-methoxy polyethylene glycols (mPEG)-Poly(D,L-Lactic Acid) (PDLLA) conjugate | Cancer therapy (Various cancer types) | Samyang | Phase 4 clinical trial | Peripheral sensory neuropathy, neutropenia |

Nanoparticle in targeting oncogenic signaling pathways

Signal transduction pathways play a crucial role in cellular functions like survival, growth, differentiation and metabolism. In the case of cancer, such signaling pathways remain altered, leading to uncontrolled proliferation, immortality and tumorigenesis. Researchers have focused on identifying the drug targets to inhibit oncogenic signaling pathways [28]. Classically, humanized antibodies and small molecule inhibitors have been used as potential inhibitors to target such oncogenic pathways. But nanotherapy has helped target cancer cells selectively without causing toxicity to the healthy cells. The following section mentions key signaling pathways responsible for tumorigenesis and the approaches taken to target such pathways.

Targeting receptor tyrosine kinase (RTK) pathway for developing anticancer therapy

Receptor tyrosine kinase (RTK) plays a crucial role in major cellular processes like proliferation. Growth factors bind to RTKs, resulting in the dimerization and activation of RTKs. The activation of the intracellular kinase domain of RTKs triggers downstream pathways (Figure 8) [28]. Different types of RTKs have been identified depending on growth factor ligands (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor...
[VEGFR], fibroblast growth factor receptors [FGFR], platelet-derived growth factor receptor [PDGFR] etc.). In cancer, RTKs are aberrantly activated and their mutations lead to various disorders. Therefore, RTKs and their ligands remain a potential drug target [28]. The inhibitors are mentioned in Figure 8.

Kulkarni et al. found that multi-receptor tyrosine kinase inhibitor (XL184) loaded liposomes mediated nanoscale medicine improves intratumoral concentration, enhances antitumor efficacy and reduces toxicities [88].

Targeting the downstream signaling pathways also act as an alternative strategy. Mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase PI3K-AKT-mTOR (mammalian target of rapamycin) pathways are two critical downstream pathways [28].

Targeting mitogen-activated protein kinase (MAPK) signaling for developing anticancer therapy

MAPK pathway comprises a series of proteins like rat sarcoma virus (RAS), rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase 1/2 (ERK 1/2). This pathway is up-regulated in most cancer types and responsible for abnormal proliferation leading to tumorigenesis. RAS, RAF and MEK gained the most attention as therapeutic targets [28]. The progress in the therapeutic strategy targeting MAPK pathway using small molecule inhibitors is mentioned in Figure 8.

Researchers found that PD98059, a selective MAPK inhibitor, conjugated with hexadentate-poly-D,L-lactic acid-co-glycolic acid polymer potentiate the anticancer efficacy of cisplatin chemotherapy [89].

Targeting phosphoinositide 3-kinase (PI3K) pathway for developing anticancer therapy

Phosphoinositide 3-kinase (PI3K) pathway is responsible for cellular processes like proliferation, growth, survival and apoptosis. This pathway is mutated in 30% of all human tumors. Activated RTKs set off several downstream signaling cascades, especially protein kinase B (Akt) and mammalian target of rapamycin (mTOR), responsible for various cellular functions [28]. The small molecule inhibitors targeting this oncogenic signaling pathway are mentioned in Figure 8.

Utilizing the nanotechnology, Harfouche et al. found that encapsulating LY294002, a PI3 kinase inhibitor into biodegradable PLGA nanoparticle causes successful inhibition of Akt phosphorylation resulting in the inhibition of proliferation [90]. Sengupta and co-workers have rationally conjugated PI3K inhibitors (PI103 and PI828) using a cholesterol-based derivative, enabling supramolecular nano assembly with L-α-phosphatidylcholine and DSPE-PEG [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] to achieve increased antitumor efficacy [91]. They have also suggested that a rational combination of cis-platinum nanoparticles and a PI3K-targeted therapeutic remains a potential therapy for breast cancer [92]. Free nanoparticles or nanoparticles carrying different therapeutic agents like oligonucleotides, cytotoxic drugs, antibodies, etc., have been used to target different oncogenic pathways (Table 5).

Another approach to target oncogenic signaling pathways is mediated by siRNA delivery, a component of gene therapy. Peptides have also been used as a molecular transporter-based nano-system to deliver siRNA targeting signaling pathways [86,105,106,107]. This is discussed in the later section of this review.

Nanoparticle in tumor angiogenesis

Angiogenesis is a phenomenon of the formation of the new blood capillaries out of pre-existing blood vessels. This phenomenon is essential for wound healing [108–111]. Cancer metastasis is also positively correlated with angiogenesis [112]. Therefore, blocking angiogenesis is a practical approach to inhibit cancer progression. Commonly available anti-angiogenic therapy harbors any of these two strategies: (1) damaging the existing blood vessels or (2) preventing the formation of new blood capillaries [113]. Anti-angiogenic therapy is different from commonly used tumor-targeted chemotherapy. It selectively targets the tumor-associated vasculature instead of the tumor cells, shows increased bioavailability for systemically administered drugs compared with tumor-targeted therapy and requires a low administration dose, leading to lesser systemic toxicity [113,114].

In spite of these advantages, chemotherapy-mediated anti-angiogenic therapy suffers from certain limitations. The tumor vasculature remains unreachable to most of the anti-angiogenic inhibitors. Nanotechnology has become an advanced and effective method to address this problem. Nanoparticle-mediated delivery of therapeutics has been achieved following both passive and active targeting [113]. Researchers have shown that conjugating cytotoxic drugs or angiogenic inhibitors with nanoparticles prefer to home at the tumor site following the EPR effect.
### Table 5 Nanoparticles used to target signaling pathways

| Nanocarriers | Materials/drugs | Cell line/animal model | Effects | Ref. |
|--------------|-----------------|------------------------|---------|------|
| Gelatin nanoparticles (D-NPs: gelatin nanoparticles loaded with NF-kB inhibiting decoy oligodeoxynucleotides) | NF-kB inhibiting decoy oligodeoxynucleotides (Decoy oligonucleotides (decoy ONs) epitomize an ideal pharmacological tool to selectively block NF-κB activation.) | Kupffer cells | Inhibition of NF-κB activation by D-NPs in kupffer cells (KC) D-NPs inhibit the nuclear translocation of p65, a common subunit of NF-κB. Improve survival and reduction in liver damage | [93] |
| Folate-linked lipid-based nanoparticles | NF-kB decoy | RAW264.7 | The NF-κB decoy shows an inhibitory effect in cytoplasm (inhibition of NF-kB translocation into nucleus of LPS-activated macrophages) Inhibit particular matter (size <2.5μm) (PM2.5) induced neuroinflammation | [94] |
| Fisetin nanoparticles (FN) (Fisetin, a natural flavonoid) | No cargo | C57BL/6 mice primary astrocytes | Restrict PM2.5 exposure-induced NF-κB signaling activation. Decrease PM2.5-induced astrocytes activation. Reduce pro-inflammatory cytokines IL-1β and TNF-α | [95] |
| mPEG-PLGA nanoparticles | Benzyloactonine | RBCs, RAW264.7 cells | Inhibit the expression of NF-κB p65 Inhibition of NF-κB signaling to reduce inflammation | [96] |
| Silica nanoparticles (MSN-mesoporous silica nanoparticles) | NF-κB p65 antibody (p65, also known as RelA) | Balb/c mice | Translocation and cell signaling transduction (the nanoparticle binds to p65, forming a complex, thereby inhibiting the entry of p65 into nucleus) | [97] |
| Nano-Selenium (Nano-Se) | No cargo | Albino wistar rats | Exhibit negative NF-κB immune expression. Reduces pancreatic injury and improves pancreatic functions | [98] |
| Astragalus polysaccharide nanoparticles (Astragalus polysaccharide (APS) is a water-soluble heteropolysaccharide with bioactive effects, A. Membranaceus stems or dried roots derivative) | No cargo | H9c2 cells/ C57BL/6 mice | Inhibition of TLR4/ NF-κB pathway activation Decrease the secretion of proinflammatory cytokine | [99] |
| Niosome nanoparticle (vesicles composed of biodegradable non-ionic surfactants, which is an alternative to liposomes) | Curcumin | Human glioblastoma stem-like cells (GSCs) | Reduce the mRNA expressions of NF-κB and IL-6 and increase the expression of Bcl2 Induce cell cycle arrest, ROS generation and apoptosis Anti-tumor effect | [100] |
| ABI-009 (albumin-bound-rapamycin nanoparticle) | Rapamycin | Gastroenteropancreatic or lung neuroendocrine tumors patients | mTOR pathway inhibitor targeting cells with TSC1/TSC2 genes mutations | [101] |
| Mesoporous silica nanoparticles | γ-secretase inhibitors (GSIs) | FVB/N adult mice | MSNPs carrying GSIs used block Notch signaling | [102] |
| Gold nanoparticles (AuNPs) | No cargo | C3H/HeN mice, NOD-SCID mice | AuNPs could deactivate TGF-β1(cys-rich protein) by directly binding to the cysteine buried inside the protein through covalent bonds (S–Au bonds ≈ 40 kcal mol⁻¹), disrupting the disulfide bond in the protein, thus destroying the structure and unfolding the protein. | [103] |
| Anthothecol-encapsulated PLGA-nanoparticles (Antho-NPs) | Anthothecol (Anthothecol, is a limonoid isolated from a plant named Khaya anthotheca (Meliaceae), which acts as an antimalarial compound) | AsPC-1,PANC-1 and Mia-Paca-2 cell | Antho-NPs are found to actively inhibit the expression of Gli, Patched1, Bcl-2 and CyclinD1 in pancreatic CSCs. Antho-NPs suppresses cell motility, migration and invasion by up-regulating E-cadherin and inhibiting N-cadherin and Zeb1 | [104] |
### Table 6 Nanoparticles used for anti-angiogenic therapy

| Nanoparticle | Cargo | Used against | Comments | Ref. |
|--------------|-------|--------------|----------|------|
| HPMA         | TNP-470 (Capiostatin) | Human melanoma, lung carcinoma | Prevents crossing of blood–brain barrier (BBB), limiting neurotoxicity | [117] |
| Aminobisphosphonate drug alendronate (Fosamax) and paclitaxel/TNP-470 | Osteosarcoma | Inhibits bone metastasis | [118] |
| Radionuclidelabeled, cyclized RGD peptide | Solid tumors | Used for diagnosis and therapeutic application | [119] |
| PLGA nanoparticle encapsulated within PEG linked lipid envelop | Doxorubicin (covalently attached to inner PLGA core) and anti-angiogenic agent (combretastatin) | Melanoma | Termed as “nanocell,” shows an improved therapeutic index with reduced toxicity | [115] |
| PEGylated polyethyleneimine (PEI) consisting RGD peptide PEGylated polyethyleneimine (PEI) consisting RGD peptide | sFlt-1 gene | Colon carcinoma | Blocks VEGF binding to membrane-bound Flt-1 receptor and inhibits proliferation | [120] |
| Chitosan coated poly-isohexylcyanoacrylate nanoparticle | Anti-RhoA siRNA | Breast cancer mouse xenograft model | Inhibits tumor growth and metastasis | [122] |
| Boronated polyamidoamine dendrimer | VEGF, | Colon carcinoma in mice | Shows anti-angiogenic effect | [123] |
| Monomethoxy-polyethylene glycol/polyactic acid copolymer | TNP-470 | Mouse melanoma | Shows an improved therapeutic index with reduced toxicity | [115,116] |
| Poly(ε-caprolactone)-polyethylene glycol (PCL-PEG) | Cyclic RGD pentapeptide (conjugated) and Doxorubicin (loaded) | Kaposis's sarcoma | Shows an improved therapeutic index with reduced toxicity | [125] |
| Ata-Pro-Arg-Pro-Gly (APPRGC) peptide (for active targeting), PEG and hydrophobic anchor distearylphosphatidylethanolamine (DSPE) | Adriamycin | Colon carcinoma | Shows antiangiogenic effect | [126] |
| Neutral liposome | Protein activated receptor-1 (PAR-1) siRNA | Mouse melanoma | Inhibits metastasis | [127] |
| Fullerene | Doxorubicin | Mouse melanoma | Shows anti-angiogenic effect | [119] |
| Dextran coated iron oxide nanoparticles | Radiolabeled anti-VEGF monoclonal antibody | Liver cancer in mice | Destruction of tumor with increased imaging resolution | [128] |
| Folate receptor targeted superparamagnetic iron oxide nanoparticle | Doxorubicin | Liver cancer | Does not show systemic toxicity | [129] |
| PEGylated gold nanoparticle | Doxorubicin | Liver cancer in mice | Shows antitumor activity | [130] |

[115,116]. Active targeting has also been effective in targeting angiogenesis. Anti-angiogenic therapy harbors targeting VEGFR, αvβ3 integrins and other angiogenic factors. Synthetic peptides having the recognition site for integrins (cyclic Arginine-Glycine-Aspartic acid [cRGD]) have been widely used for targeted nanotherapy [113]. A plethora of nano-vectors have been reported by researchers for nanotechnology-based anti-angiogenic therapy, including polymeric nanoparticles, liposomes and micelles, dendrimers, carbon nanostructures, inorganic nanoparticles (e.g., gold, silver and iron oxide), etc. Recent nanotechnology-based anti-angiogenic therapies also use a gene silencing-based approach using therapeutic genes or siRNA [113].

A few reports on nanotechnology-based anti-angiogenic therapy are provided in Table 6.

### Nanoparticle-mediated gene therapy for cancer

Gene therapy is the modulation of gene expression towards treating a disease by cellular delivery of therapeutic nucleic acid. It holds unique promise in alteration of specific tumor genes functioning via gene addition, gene correction or
gene knockdown [16]. Several approaches of cancer gene therapy include (1) suicide gene therapy: introduction of an enzyme expressing transgene into the cell that converts inactive prodrug into cytotoxic metabolite for host cells, (2) gene silencing: suppression of gene expression by RNAi techniques like siRNA, shRNA, antisense oligonucleotide, miRNA, etc., and (3) DNA vaccine: introduction of specific antigen encoding plasmid DNA into the cell to induce immune response.

Gene therapy shows the potential to deal undruggable targets to treat cancer as compared with conventional treatment by targeting cancer associated genes. Gene therapy can provide a solution to low bioavailability, reducing immune system based recognition and delivery of the gene regulators [131]. The fundamental challenge in the engineering of gene therapy is the development of clinically safe and effective delivery vectors. In clinics, both viral and non-viral mode of delivery is being used for systemic gene delivery [132]. The viral delivery systems are associated with various safety concerns as well as limited payload capacity and difficulty in large-scale production [16]. These factors led to the development of interest toward non-viral synthetic vectors for gene therapy. The non-viral vectors are advantageous in providing higher safety profile, low cost, large scale manufacturing potential, stability and higher payload [132]. Nanoparticle and nanoscale gene delivery vectors have emerged as efficient candidates for intracellular or systemic gene delivery.

Nanoparticle exploitation for gene delivery can be categorized into four groups: (1) lipid-based nanoparticles, (2) polymer-based nanoparticle, (3) peptide-based nanoscale material and (4) inorganic nanoparticles.

**Lipid-based nanoparticles**

Lipid-based nanoparticles are the most widely used non-viral gene delivery vehicle [132, 133]. Cationic liposomes are amphiphilic molecules which are made up of cationic polar head group, a hydrophobic domain and a linker connecting the polar head group with the non-polar tail. This cationic liposomes are routinely used for gene delivery [134]. Incorporation of longer lipidic chain (having around 18 methylene group, which can span the whole membrane) having unsaturation and small polar head facilitates the formation of conical shaped lipid in anionic membrane environment, which promotes the hexagonal phase transition of the lipid bilayer from the lamellar phase [135]. Hexagonal phase of the lipid bilayer is more fusogenic than lamellar phase. This transition of lamellar phase to hexagonal phase of lipid bilayer leads to cellular internalization and endosomal release of the internalized lipid-based nanoparticle [135]. Lipid nanoparticle containing ionizable lipids are designed in a way that it gets protonated at endosomal pH range (4.5–6.5). The protonated cationic lipid interacts with the anionic lipid of the endosomal membrane, leading to the transition of the lamellar phase to the hexagonal phase of lipid bilayer. Several liposomal nanoformulations have been in clinical development like DOTAP-cholesterol, GAP-DMORIE-DPyPE, etc. The FDA approval of Alnylam's patisiran in 2018, is the first ever drug to successfully harness RNA interference to silence disease associated gene expression was a key milestone. Further, FDA approved lipid based nanoparticles like givosiran, lumasiran established a benchmark for lipid nanoparticle based drugs. Hou et al. have discussed in detail about the use of lipid based nanoparticles for gene delivery, their drawback and engineering principles for engineering next-generation improved lipid based nanoparticles [136].

**Polymer-based nanoparticles**

The chemical diversity and functionalization potential of cationic polymer based nanoparticle makes it an attractive class of non-viral gene delivery vehicle. Polymers are considered as inert but certain modification by biologically active agents and counterions like spermidine or cell penetrating peptides improves the surface functionalization, nucleic acid loading and particle transfection [16] PLGA nanoparticle is capable of delivering nucleic acid with minimal toxicity but exhibit low transfection efficiency [16]. PLGA nanoparticles are surface functionalization with cell targeting or cell penetrating peptides to improve nucleic acid loading and cell penetrability. The condensation of negative phosphate bonds of nucleic acid with the cationic polymers into polyplexes protects nucleic acid from degradation during circulation [16].

Polyethylenimine (PEI) and its variants are among the most studied polymeric materials for gene delivery. The presence of nitrogen at every third position of the polymer increases the charge density and reduces the pH [132,137]. Various polymer-based nanoparticles such as dendrimers, polyion complex micelles (PICs), cyclodextrin, etc., have also been explored greatly in gene therapy. The polymeric nanoparticle system owing to their facile synthesis and flexible properties proves to be a new promising material for developing non-viral gene delivery system. The cationic polymer can be conjugated with the negatively charged genetic material via electrostatic attraction at physiological
pH and facilitating gene delivery. Ekladios et al. have discussed in detail about the rational designing, physicochemical characteristics and advancements in different classes of polymer based delivery vehicle and their application in different fields including gene therapy [138].

### Peptide-based nanoscale material

Cell penetrating peptides (CPP) are a class of peptides facilitating the cellular internalization of nucleic acid based therapeutics either by covalent or non-covalent conjugation. The cellular uptake of the CPP peptide depends upon their sequence, structure, concentration and cell lines used for study [139]. The cellular internalization of cell penetrating peptides follow either by one or by the combination of the following mechanisms: (1) creating a transient pore in cell membrane, (2) endocytic uptake and (3) receptor mediated uptake. Depending upon the sequence, the CPP can be of cationic CPP or amphiphilic CPP.

The cationic CPPs are arginine or lysine rich short peptides. Arginine rich sequences are found to show enhanced cellular uptake. The arginine can form a more efficient bidentate hydrogen bond than the monodentate hydrogen bond formed by lysine with the anionic moieties like phosphate (PO₄³⁻), carbonate (CO₃²⁻) and sulfate (SO₄²⁻) on the cell surface [140]. These interactions facilitate the cellular internalization of the arginine or lysine residue enriched cationic peptides.

Amphiphilic peptides show enhanced cellular uptake by the formation of lipid rafts in the cell membrane. The cationic part of the CPP interacts with the negatively charged therapeutic nucleic acid and the hydrophobic part facilitates the cellular internalization of the peptide by interacting with the lipid bilayer [141,142].

N-Methylpurine DNA Glycosylase or MPG (GALFLGFLGAAGSTMGAWSQPKKRRK) peptide is a great example of amphiphilic CPP. The hydrophobic stretch of this amphiphilic CPP (underlined) adopts a transient β-sheet structure creating a temporary channel in the cell membrane allowing the peptide–nucleic acid complex to internalize [143,144]. Amphiphilic α-helical peptide like penetratin (RQIKIWFQNRRMKWKK) generally remains unstructured in an aqueous solution but tends to adopt an α-helical conformation while interacting with cell membrane [84]. Majority of CPP internalizes via endosomal pathway and are accumulated inside endosome. Two strategies employed for endosomal escapes are use of (1) conformation changing fusogenic peptides and (2) proton buffering peptides [84]. The conformation changing fusogenic peptides in endosomal pH (4.5–6.5) undergoes a conformational change and ruptures the endosomal membrane by forming an amphiphilic helix [84]. These peptides are rich in histidine and glutamic acid and are sensitive to pH change. pH sensitivity arises due to imidazole group of histidine side chain having pKₐ value of ~ 6.0 and glutamic acid side chain with pKₐ ~ 4.3 allowing easy protonation and de-protonation of these amino acids in endosomal environment.

Proton buffering peptides escape the endosomal entrapment by accumulation of proton absorbing peptides inside endosome and disrupting the endosomal membrane by proton sponge effect. Imidazole ring of histidine having a pKₐ value of nearly 6.0 shows high buffering effect by acting as a weak base inside endosome. This causes influx of protons into the endosome and osmotic swelling causing endosomal rupture. Peptides provide advantage as a delivery vehicle due to their biocompatibility, biodegradability and sheer limitless combinations and modifications of amino acid residues inducing the assembly of modular, multiplexed systems [145]. Tarvirdipour et al. have discussed in detail the designing principles and attractive features of peptide based nanoscale materials for gene therapy [145].

### Inorganic nanoparticles

This includes carbon nanotubes, magnetic nanoparticles, calcium phosphate nanoparticles, gold nanoparticles and quantum dots that are commonly used for gene delivery vehicles. The inorganic nanoparticles are resistant to microbial attacks and provide good storage stability [146]. The functionalized single-walled nanotubes are reported to enter premyelocytic leukemia and T-cell very easily; this ability is exploited to deliver nucleic acid into mammalian cells [147]. Water soluble allotrope of carbon (C60) fullerenes modified to aminofullerenes has positive charge on them. This aminofullerenes are reported to have high transfection efficacy of DNA into mammalian cells [148]. Inorganic nanoparticles are reported to have great gene delivery efficacy on surface modification. Chen et al. have discussed in great detail about the use of inorganic nanoparticle as a drug codelivery nanosystem [149]. Table 7 lists out some of the important nanoparticle based gene therapeutic approaches. Advancement in clinical studies of engineered siRNA-loaded nanoparticles has been discussed in Table 8 [150,151].
Table 7 Nanoparticle-mediated gene therapy for cancer treatment

| Type of gene therapy | Drug                                                                 | Nanoparticles used                                                                 | Cancer type/cell line                          | Effects                                                                                                                                                                                                 | Ref. |
|----------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Suicide gene therapy | Plasmid DNA encoding saporin gene                                    | U11 peptide functionalized lipid-protramine-DNA nanoparticle                      | Triple negative breast cancer (MDA-MB-231)    | Tumor size was found to be significantly reduced in in vivo mice model                                                                                                                                  | [152]|
| Suicide gene therapy | Plasmid DNA encoding Herpes simplex virus thymidine kinase (HSVtk) gene | Poly(beta-amino ester) nanoparticles                                              | Pediatric brain tumors                         | Increased median survival in in vivo mice model                                                                                                                                                    | [153]|
| siRNA-based therapy  | c-Myc siRNA                                                          | Gold-PEG nanoparticles                                                             | Adenocarcinoma                                | Reduction in tumor size by 80% in vivo                                                                                                                                                             | [154]|
| siRNA-based therapy  | Akt1 siRNA                                                           | Polyethyleneimine based nanoparticle                                              | Mouse colon cancer                             | Reduced tumor growth                                                                                                                                                                              | [155]|
| siRNA-based therapy  | Polo-like kinase-1 siRNA (siPLK1)                                   | Lipid containing lipid-based (cholesterol, DSPC, D lin-MC3-DMA, DMG-PEG and DSPE-PEG amine) nanoparticle | Glioblastoma                                   | Increased gene silencing efficiency and higher survival in mice                                                                                                                                  | [156]|
| siRNA-based therapy  | Cell division cycle-associated protein 1 (CDCA1) siRNA              | Lipid (PEG lipids, PEG-C-DMA lipids, D-Lin-DMA lipids, DSPC and PEG) nanoparticles | Hepatocellular carcinoma                      | Significant anticancer efficacy                                                                                                                                                                     | [157]|
| siRNA-based therapy  | Cyclin targeting siRNA                                               | Peptide MPG (ac-GALFLGFLGAAGS TNGAWSQP/KKKKRKKV-Cya) (Cya : Cysteamide)           | HS68 fibroblasts, HeLa, PC3, MCF-7 and SOK3-Her2 | Block cancer cell proliferation by efficient down-regulation of cyclin B1 levels                                                                                                                        | [105]|
| siRNA-based therapy  | ERK1/2 silencing siRNA                                               | Peptide c(-Arg-His-Arg-His-Arg-Lys (Lyslinocy1)-Arg-His-Arg-Lys-His-Glu-) Lys(FAM)-NH2 | Breast cancer (MDA-MB-231)                    | Down-regulation of Erk1/2 gene level in TNBC cell line MDA-MB-231                                                                                                                               | [86]  |
| siRNA-based therapy  | Raf-1 siRNA                                                          | Peptide based Modified block copolymers-poly(ethylene glycol)-poly(-caprolactone)-Tat (GP9KPRPQRPRPMPPEG-POL-Tat) | C6 cells                                      | Cell death in rat glioma cells                                                                                                                                                                       | [106,158]|
| siRNA-based therapy  | VEGF siRNA                                                           | Peptide KALA (WEAKLAKL AKALAKHLAKAL ALKAGEA)                                      | PC-3 cells                                    | EGF sequence-specific gene inhibition in prostate carcinoma in vitro                                                                                                                                | [107]|
| siRNA-based therapy  | Polo like kinase-1 siRNA                                             | Multi-walled carbon nanotubes with amino functionalization                         | Human lung carcinoma                           | Significant regression of tumor volume                                                                                                                                                             | [159]|
| siRNA-based therapy  | Cyclin B1 siRNA and survivin siRNA                                  | Calcium phosphate nanoparticles                                                    | Non-small cell lung cancer                    | Significant gene silencing, reduction in cell growth and induction of apoptosis                                                                                                                                 | [160]|
| miRNA-based therapy  | Tumor suppressor miR-31 and oncogenic miR-1323                       | Cysteamine functionalized gold nanoparticle                                       | Neuroblastoma and ovarian cancer              | Increased payload, efficient cellular uptake and reduced toxicity                                                                                                                                  | [161]|
| miRNA-based therapy  | AntimR-21 and antimR-10b                                             | uPA peptide conjugated PLGA-b-Peg nanoparticles                                   | Triple negative breast cancer                 | Reduction in tumor growth by 40%                                                                                                                                                                      | [162]|
| shRNA-based therapy  | Doxorubicin encapsulated PLGA nanoparticle and Bcl-xl shRNA         | Alkyl modified polyethyleneimine                                                  | Breast cancer cell line MCF-7                 | Increased apoptosis of tumor cells and enhanced synergistic effect in comparison with only doxorubicin encapsulated PLGA nanoparticle treatment | [163]|
| shRNA-based therapy  | Akt1 shRNA                                                           | Folate and chitosan grafted polyethyleneimine copolymer                           | Human lung carcinoma                           | Enhanced cell transfection and reduced tumorogenesis                                                                                                                                             | [164]|
| DNA vaccine          | Plasmid encoding prostate stem cell antigen                          | Catonic RALA peptide/pDNA nanoparticles                                           | Prostate cancer                               | Showed anticancer activity in vivo                                                                                                                                                                  | [165]|

Continued over
Table 7 Nanoparticle-mediated gene therapy for cancer treatment (Continued)

| Type of gene therapy | Drug | Nanoparticles used | Cancer type/cell line | Effects | Ref. |
|----------------------|------|--------------------|-----------------------|---------|-----|
| mRNA vaccine         | mRNA encoding tumor associated antigen gp100 and TRP-2 | Lipid based (DOTAP, DODAP, C12-200, cKK-E12, DOPE, DSPC, POPE, DMPC, DOPS, cholesterol, PEG, arachidonic acid, oleic acid, myristic acid) nanoparticle | Melanoma (B16F10) | Promoted enhanced cytotoxic T-cell response and reduced rate of tumor growth | [166] |

Table 8 Nanocarrier-mediated siRNA delivery systems in clinical trials

| Drug | Disease | Target | Nanoparticle | Company | Status |
|------|---------|--------|--------------|---------|--------|
| CALAA-01 | Solid tumors | RRM 2 (RNA recognition motif domain of the Rbfox family protein) | Cyclodextrin/PEG, transferrin | Calando Pharm | Terminated |
| ALN-VSP02 | Solid tumors with liver lesion | VEGF, KSP (kinesin spindle protein) | SNALP (stabile nucleic acid-lipid particles) | Alnylam Pharm. | Completed |
| siRNA–EphA2–DOPC | Advanced cancer | EphA2 (tyrosine kinase)(a key effector of the MEK/ERK/RSK pathway) | Liposome | M.D. Anderson Cancer Center | Not completed yet |
| FANG | Ovarian tumors | FURIN (a protease enzyme) | Liposome | Gradalis, Inc. | Active |
| Atu027 | Advanced or metastatic solid tumors | PKN3 (protein kinase N3) | Liposome | Silence Therapeutics | Completed |
| siG12D LODER | Pancreatic ductal adenocarcinoma | KRASG12D | Polymer matrix | Silenseed Ltd. | Ongoing |
| TKM-080301 or TKM-PLK1 | Solid tumors | PLK1 | SNALP | Tekmira Pharma | Completed |
| DCR-MYC | Hepatocellular carcinoma, solid tumors, non-Hodgkins lymphoma, multiple myeloma, pancreatic neuroendocrine tumors | MYC | Systemic/IV infusion | Dicerna Pharmaceuticals | Terminated |

Nanoparticle-mediated combination therapy against cancer

Combination therapy, a treatment modality involving combination of two or more therapeutic agents, has now become the cornerstone of cancer therapy since single drug based monotherapy failed to provide a considerable therapeutic response. Enhanced therapeutic potential, reduced toxicity and prevention of drug resistance mediated by combination therapy have hugely increased the therapeutic response of cancer patients. Combination therapy can be designed in two different ways. First, targeting of different molecular pathways by multiple drugs can lead to delayed cellular adaptation and oncogenic mutations. Second, targeting the same pathology could be helpful in the development of synergistic interaction of multiple drugs with higher efficacy and target selectivity. Synergistic interaction is best described by the Chou-Talalay method where combination index (CI) is less than 1 [167,168]. Boshuizen et al. suggested that a synergistic drug interaction in a combination therapy can be rationally designed by invoking several principles: (1) multiple targeting of a signaling pathway, (2) maximal driver pathway inhibition, (3) targeting agents responsible for signal reactivation, (4) enhanced synthetic lethality, (5) targeting heterogeneous and drug resistant cell populations in a tumor, (6) targeting immune cell function and tumor microenvironment modulation and (7) neoadjuvant therapies [169]. Combination therapy also employs repurposing of drugs that were initially used for diseases other than cancer. This approach saves the high cost and time required for granting FDA approval as the repurposed drug is generally an FDA approved drug, thus cutting the cost of the treatment [170]. The synergistic agents involved in modern combination therapies should ideally have a different pharmacological mechanism of action, exhibit no cross-resistance or overlapping toxicities and target tumor heterogeneity [171]. By integrating the knowledge and progress made in the field of mechanisms responsible for tumorigenesis, tumor microenvironment, therapy response and cancer heterogeneity, an effective treatment can be designed [169].
Nanoparticles have emerged itself as a potent tool to be used in combination therapy as they provide longer circulation time of biologically active drug, reduced toxicity, improved drug solubility, controlled release and has specific target potential [172]. Gurunathan and co-workers have elaborately described different types of nanoparticles mediated combination therapies [173]. The rationale for designing nanoparticle-mediated combination therapy for cancer treatment is provided in Figure 9. In Table 9, we have enlisted examples of nanoparticle-mediated combination therapy for treating different types of cancer and their advantages over monotherapy.

In recent years, there has been an increase in the number of reports of multifunctional nanoparticle mediated combination therapy aided with peptides. Some of the advantages of peptide-mediated combination nanotherapeutics are tumor targeted delivery, presentation of tumor antigens for elicited immune response, sensitization of drug resistant cells and reduced side effects [187]. Mehrotra et al. and Mallick et al. have elaborately enlisted different types of peptide-based combination nanotherapeutics [187,188]. We have enlisted some of them in Table 10.

However, the current combination therapy treatment in cancer, especially in the case of metastatic breast cancer, is still loaded with flaws having moderate efficacy but additive toxicity [18]. Drugs, when administered separately without any modification, tend to not only cause an additive anticancer effect but also result in augmented adverse effects of each drug as well. For achieving synergistic interactions, a definite ratio of the two free drugs needs to be maintained. This ratio is generally determined in in vitro studies, and it is crucial that this ratio is to be maintained at tumor site. The problem arises because in in vivo model it becomes virtually impossible to deliver the determined ratio of free drugs in the tumor site. This is mainly due to the different pharmacokinetic properties, elimination and metabolism rates of individual drugs. Delivery of non-fixed ratio of drugs can give rise to antagonistic interactions and drug resistance in cancer cells [257]. For example, irinotecan and cisplatin (both cytotoxic drugs) show synergistic interaction at 4:1 ratio but strong antagonistic interaction at 1:1 ratio and in the case of many anticancer drugs, when the effective dose is below its optimum dose, it may give rise to drug resistant cells in tumor [257]. Another complication arises when the free drugs need to be administered by different routes and at different schedules. HER2 targeted combination therapy with Trastuzumab (TRZ, a monoclonal antibody binding to HER2 receptor) and lapatinib (a tyrosine kinase inhibitor blocking HER2 and EGFR pathways) have two different routes of administration. Lapatinib is administered daily as an oral formulation, while TRZ is given weekly as an intravenous drug. This difference in schedules and ways of administration of these two drugs makes the management of pharmacokinetic and pharmacodynamic profiles more challenging and virtually impossible to achieve uniform temporal and spatial co-delivery [18]. Most standard chemotherapy guidelines prefer sequential delivery of free drugs over concurrent delivery due to toxicity issues. This also prevents the right temporal delivery of drugs with dissimilar pharmacokinetic properties [258].

To address these issues, nanoparticle-mediated co-delivery of those drugs may ensure the desired spatio-temporal delivery and controlled release of drugs while maintaining the synergistic fixed ratio (Figure 10) [258]. Nanocarrier mediated co-encapsulated drugs having physically different properties show similar pharmacokinetic profiles, extended drug half-life, solubility, tumor accumulation and synergistic drug interactions when compared with free drugs administered sequentially or concurrently [18,257]. Cytrabine (an antimetabolite chemotherapeutic drug) and danorubicin (a cytotoxic chemotherapeutic drug) has distinct pharmacokinetic properties as free drugs but when co-encapsulated in liposomal nanocarrier as Vyxeos® exhibit similar pharmacokinetic profile [257]. Nanocarrier mediated co-delivery of drugs enables targeting multiple signaling pathways, overcoming drug resistance and immunosuppression by cancer [257].

Various delivery systems widely used for co-delivery of two drugs include liposomes, dendrimers, polymeric nanoparticles and water-soluble polymer conjugates. Lee et al. and Gurunathan et al. have elaborately reviewed nanoparticle-mediated co-delivery of two or more drugs for cancer therapy as described in Table 11 [18,173].

In some instances, co-delivery of drugs in a single nanoparticle suffers from drug leakage and poor loading efficacy [259]. To overcome this problem, researchers have conjugated two anticancer drugs via suitable covalent linkages and then subsequently encapsulated the conjugate in a nanoparticle. For example, Aryal et al. have used ester linkage for conjugating paclitaxel and gemcitabine and loaded the drug conjugate into a PLGA nanoparticle. Hydrolysis of this ester linkage at mildly acidic pH (pH 6) of endosomal environment resulted in two separate functional drug fragments [260]. Matlapudi et al. have conjugated Imatinib mesylate (abbreviated as IM, a tyrosine kinase inhibitor) and 5-fluorouracil (abbreviated as FU, an antimetabolite) by hydrolysable succinyl linker (abbreviated as Su) which forms amide linkage with each drug. This drug conjugate IM-Su-FU was incorporated in a human serum albumin (HSA) nanoparticle. This HSA encapsulated drug conjugate (IM-Su-FU) nanoparticle exhibited higher anticancer efficacy in in vivo lung cancer model compared to free drugs and only IM-Su-FU conjugate. Pharmacokinetic analysis of this nanoparticle exhibited improved elimination rate, half-life and mean residence time (MRT) than free drug and only IM-Su-FU conjugate [261].
Table 9 Nanoparticle-mediated combination therapy with small molecules and nucleotide-based anticancer drugs

| Drug 1                                      | Mode of action of drug 1 | Drug 2                        | Mode of action of drug 2 | Indication                  | Comments on combination                                                                 | Ref.  |
|---------------------------------------------|---------------------------|-------------------------------|---------------------------|-----------------------------|-----------------------------------------------------------------------------------------|-------|
| Sterically stabilized liposomal DOX        | Cytotoxic                 | Liposome containing Bcl-2 antisense oligodeoxynucleotide, G3139 | Gene silencing            | *In vivo* melanoma model     | Combination showed delayed tumor growth and increased accumulation of DOX in tumor site than monotherapy | [174] |
| Liposomal daunorubicin                      | Antitumor antibiotic      | Cytarabine                    | Antineoplastic anti-metabolite | Patients having refractory or recurring acute myeloid leukemia | The combination has significant antileukemia activity with low toxicity. Liposomal encapsulation of daunorubicin changes the pharmacology profile to decrease toxicity and increase delivery to tumor sites | [175] |
| Liposome-entrapped, ends-modified raf antisense oligonucleotide (LERaON) aGD2-SIL(DOX) Sterically stabilized immunoliposomes(SIL) encapsulated with DOX, targeted to the disialoganglioside receptor GD2 | Gene silencing            | Cisplatin/epirubicin/ mitoxantrone/docetaxel/ gemcitabine | Chemotherapeutic agents     | *In vivo* pancreas or pancreatic cancer model | Increased tumor growth inhibition as compared with single agents | [176] |
| Non-pegylated liposomal Doxorubicin         | Cytotoxic                 | Cyclophosphamide/ docetaxel   | Cytotoxic                 | Patients with metastatic breast cancer | Use of non-pegylated liposomal Doxorubicin in combination with other drugs can be used for the first-line therapy against metastatic breast cancer | [178] |
| RGD SSL-DOX (RGD-SSL- RGD-modified sterically stabilized liposomes) | Cytotoxic                 | RGD-lipo-siRNA silencing      | P-glycoprotein            | *In vivo* mouse model of drug-resistant MCF7/A breast cancer tumor | Combination exhibited higher in vitro toxicity and greater inhibition of tumor growth | [179] |
| VEGF siRNA in polycation liposome-encapsulated calcium phosphate nanoparticles | Gene silencing            | Doxorubicin                   | Cytotoxic                 | *In vivo* mouse model of breast cancer | Combination showed significant tumor growth and angiogenesis inhibition | [180] |
| Polymeric nanoparticle-encapsulated curcumin | Cytotoxic                 | Gemcitabine                   | Cytotoxic                 | *In vivo* mouse model of human pancreatic cancer | Enhanced tumor growth inhibition compared to single agents. | [181] |
| VOR-POEOMA Vorinostat encapsulated into poly(ethylene glycol) monomethacrylate (POEOMA)-based disulfide cross-linked nanogels. C60 fullerene | Histone deacetylase inhibitor | ETOPO-POEOMA Etopside encapsulated into poly(ethylene glycol) monomethacrylate (POEOMA)-based disulfide cross-linked nanogels. Doxorubicin | Topoisomerase II inhibitor | Human cervical HeLa cancer cells | Combination showed enhanced synergistic cell killing efficiency | [182] |

Continued over
### Table 9 Nanoparticle-mediated combination therapy with small molecules and nucleotide-based anticancer drugs (Continued)

| Drug 1 | Mode of action of drug 1 | Drug 2 | Mode of action of drug 2 | Indication | Comments on combination | Ref. |
|--------|--------------------------|--------|--------------------------|------------|-------------------------|------|
| Anti Bcl-2 siRNA loaded polyethylenimine (PEI)-conjugated graphene oxide (PEI-GO) | Gene silencing | DOX loaded polyethylenimine (PEI)-conjugated graphene oxide (PEI-GO) | Cytotoxic | Human cervical HeLa cancer cells | Sequential delivery exhibited synergistic effect. Codelivery showed no significant synergistic effect on killing cancer cells | [184] |
| Palladium nanoparticles (PdNPs) | Cytotoxic | Trichostatin A (TSA) Histone deacetylase inhibitor | Human cervical HeLa cancer cells | Combination exhibited synergistic interaction and also had an increased effect on cytotoxicity, oxidative stress and caspase-3/9 activity | [185] |
| Palladium nanoparticles (PdNPs) | Cytotoxic | Tubastatin A (TUB-A) Histone deacetylase inhibitor | TNBC cell line MDA-MB-231 | Combination had a more pronounced effect on the inhibition of HDAC activity and enhanced apoptosis of cells | [186] |

### Figure 10. Schematic representation of nanoparticle-mediated ratiometric delivery of drug combination

The scheme represents the pharmacokinetics and biodistribution of ratiometric drug combination. Drug combination delivered sequentially or concurrently either by similar or different route of administration show a non-fixed ratio in biodistribution of both the drugs. Nanoparticle mediated delivery of dual drugs maintain a fixed ratio of biodistribution of drug combinations resulting in higher therapeutic efficacy (This image was drawn based on the information provided in Zhang et al. 2016 [258], Figure 4). Adapted from “Body (female, teen)”, by BioRender.com (2021). Retrieved from https://app.biorender.com/illustrations/61d7dc25883c8d00a22cf5c8.
Table 10 Nanoparticle-mediated combination therapy having peptide-based anticancer drug

| Peptide + Combination drug | Drug details | Indications | Comments | Ref. |
|----------------------------|--------------|-------------|----------|------|
| dPPA peptide + paclitaxel prodrug + photosensitizer | dPPA-1 peptide –NYSKPTDRQYHF (anti-PD-L1) paclitaxel- cytotoxic photosensitizer dPPA peptide –NYSKPTDRQYHF (anti-PD-L1) paclitaxel- cytotoxic photosensitizer | In vivo, breast cancer and lung metastasis | Increased NK cell and T-cell activation causing inhibition of complete lung metastasis and at least 10% decrease in primary tumor volume as compared with either alone or combination of paclitaxel and photosensitizer | [189] |
| NuBCP-9 (Bcl-2 inhibitor) peptide + paclitaxel | NuBCP-9 –Ac-FSRLHSLLGC-NH₂ paclitaxel-cytotoxic | In vivo, breast cancer | Combination leads to reduced IC₅₀ value (100-fold) in paclitaxel resistant cells and shows complete tumor inhibition in syngeneic mouse model as compared with only paclitaxel | [190,191] |
| Acetylated rapeseed protein isolate derived peptides + DOX | From hydrolyzed ARPI peptides screened. Sequences are AGS, PAS and YT. DOX- cytotoxic | In vivo, breast cancer | Enhanced cellular uptake and nuclear transport in comparison with free DOX. Increase in tumor inhibition and diminished DOX-associated cardiotoxicity. | [192] |
| PML + BIM (Bcl-2 inhibitor) peptide + iNGR | PML- p53 activating) peptide- TSFAEYWNLLSP BIM- Bcl-2 inhibitor) peptide-MRPEWIAGELIRI050(DEFNAYARRV iNGR- CD-13) targeting peptide cyclic CRNGRGPD | In vivo, colorectal cancer | Increased tumor inhibition (15%) with significant improvement in biosafety and reduced body weight loss compared with only DOX. | [193,194] |
| aFLT1 peptide + DOX | aFLT1 peptide- binds VEGFR1 isoform- GNQWR-NH₂ DOX-cytotoxic | In vivo, breast cancer | Two-fold increase in tumor inhibition | [195] |
| KLA + DOX | KLA - mitochondrial membrane disruptor) peptide KLA KLAKLAKLAKLAK DOX-cytotoxic | In vivo, colorectal cancer | Marked increase in tumor inhibition and mean survival time as compared with only DOX | [196] |
| R8 modified AVPI peptide with pS3DNA+DOX | R8 modified AVPI peptide- cell penetrating apoptotic peptide- AVPIR8 pS3 DNA- induces apoptosis DOX-cytotoxic | In vivo, resistant breast cancer model | 4.4- and 2-fold increase in tumor inhibition in drug resistant mouse model as compared with equal and high free DOX dose, respectively | [197] |
| KLA peptide + chlorin e6 | KLA peptide- membrane lysis peptide-D-(KLA KLAKLAKLAK)₂ chlorin e6- generates singlet oxygen causing membrane disruption | In vitro, cervical carcinoma | Tenfold reduced IC₅₀ value compared to only peptide | [198] |
| Wilms tumor gene (WT1) peptide-based vaccine+gemcitabine | WT1 peptide- target antigens for cancer immunotherapy C1TYWQMNML Gemcitabine-cytotoxic | Patients with advanced pancreatic cancer | Combination was found to be more effective than gemcitabine alone and combination therapy was well tolerated | [188,199] |
| Cep55/c10orf3_193 + Cep55/c10orf3_402 + Cep55/c10orf3_283 | VYVKGLLAKI + EFAITEPLVTF + LYSQRRADVQHL antigenic peptides | Patients with colorectal carcinoma | Vaccination involving peptide mixture could be more efficacious compared with single peptide to treat colorectal carcinoma patients | [188,200] |
| “Peptide cocktail” | RNF43-721: NSQPVWLCL TOMM34–299: KLROEVQKQNLI KOC1(IMP-3)-508 (KTVNELQNL) 3 peptides derived from oncoantigens VEGFR1–1084: SYGVLLWEI VEGFR2–169: RFVPDGNRI 2 peptides derived from angiogenesis factors | Patients with advanced colorectal cancer | Treatment with multiple peptides was well tolerated without systemic adverse effects. The median overall survival time was 15.5 months | [188,201] |
| 7-peptide cocktail vaccine | RNF43: NSQPVWLCL TOMM34: KLROEVQKQNLI FOXM1: ITTVIIEIDHF MELK: EYCPGNLFL HJURP: KWLSIPWIKI 5 tumor antigen-derived peptides VEGFR1: SYGVLLWEI VEGFR2: RFVPDGNRI 2 vascular endothelial growth factor receptor-derived peptides | Patients with metastatic colorectal cancer | Patients exhibiting positive cytotoxic T lymphocyte responses to all seven peptides had longer overall survival compared with other patients and this therapy is recommended for further trials | [188,202] |
Table 10 Nanoparticle-mediated combination therapy having peptide-based anticancer drug (Continued)

| Peptide + Combination drug | Drug details | Indications | Comments | Ref. |
|----------------------------|--------------|-------------|----------|------|
| KIF20A-derived peptide + gemcitabine | KIF20A-peptide for trafficking of molecules and organelles during the growth of pancreatic cancer- KVLRLRPLL Gemcitabine- cytotoxic | Patients with advanced pancreatic cancer | The disease control rate was 44%. The median survival time after first vaccination was 173 days and 1-year survival rate was 11.1%. No severe adverse effects of grade 3 or higher were observed | [188,203] |
| GV1001 + gemcitabine | GV1001 - telomerase peptide- EARPALLTSRLRFPK Gemcitabine- cytotoxic | Patients with advanced pancreatic cancer | This combination appears to be safer with transient and weak immune responses | [188,204] |
| E75 + GM-CSF | E75- immunogenic peptide derived from the HER2 protein. KIFGSLAF GM-CSF = granulocyte-macrophage colony-stimulating factor | Patients with node-positive or high-risk node-negative breast cancer | Therapy considered safe with a suggestion of clinical benefit. Has been licensed for commercial development | [188,205] |
| FNIII14+ Ara C | FNIII14-peptide derived from fibronectin- TEATITOLEPGETYTIYIAL Ara C – anti metabolic agent cytarabine/arabinosylcytosine | In vivo minimum residual disease (MRD) mice model | In mouse with MRD in bone marrow, 100% survival was achieved with this combination, whereas Ara C alone prolonged survival only slightly | [188,206,207] |
| D-K/L 3 + IL-12 | D-K/L 3 - induces necrosis in cancer cells-Ac[(D)(K6L9)]-NH2 IL-12- pro-inflammatory cytokine-interleukin 12 | In vivo murine melanoma model | This combination showed long-term tumor growth inhibitory effect | [188,208] |
| VEGFR2–169 + S-1 + cisplatin | VEGFR2–169-RF-PDGQRRI S-1 - combination drug tegafur/gimeracil/oteracil cisplatin - cytotoxic | Patients with advanced gastric cancer | The combination therapy was highly effective and well tolerated in advanced or recurrent gastric cancer | [188,209] |
| LD8 + DOX | LD8 – gramicidin A inspired peptide Boc-(A-P)V-L-P-A-I-V-C-P-A-I-L-DW- OMe DOX- cytotoxic | In vitro TNBC cell line MDA-MB-231 | LD8-DOX-NP induces G2 phase cell cycle arrest and apoptosis of MDA-MB-231 | [210] |

Challenges and future prospect of nanoparticle-mediated combination therapy

Nanoparticle-mediated combination therapy has shown great potential in treating metastatic and drug resistant cancer [262]. Combination therapies involving cytotoxic drugs, signal transduction inhibitors, immunotherapeutic drugs, epigenetic agents and priming with apoptotic drugs have shown promising possibilities for cancer therapeutics [258]. The success of nanoparticle mediated combination owes to its “3R” delivery principle, i.e., right place, right dose and right time. To gain the benefits of nanocarrier mediated combination therapy, different databases and drug development platforms are developed. EMBASE® and Ovid MEDLINE® are databases used for the co-delivery of drugs. The drug combination development platform CombiPlex screens dual drugs and makes nanoscale formulation for nanocarrier mediated co-delivery of drugs. CombiPlex platform first determines the synergistic ratio of free drugs and then chooses a suitable nanocarrier to coordinate the pharmacokinetics of the free drugs and ensures the drugs reach the tumor site in the desired ratiometric manner. CPX-351, developed from CombiPlex platform is an FDA approved drug used for treating AML in adults. CPX-351 comprises cytarabine and daunorubicin in a synergistic ratio encapsulated in a liposomal carrier [257].

Although nanoparticle-mediated combination therapy has immense potential, but the regime of nanoparticle-based combination therapy is far from being able to cure metastatic cancers. 0.7% is the median efficiency of delivery of the injected nanoparticle to the desired tumor site [24]. Additionally, the five-year survival rates of most malignant cancer are still quite low and most combination approaches still depend on cytotoxic approaches instead of molecularly targeted anticancer agents or nanoparticle mediated combination approach [263]. Saptura et al. has shown antagonistic drugs interactions used in combination can suppress the clonal expression of singly-resistant cells in in silico model [264]. So antagonistic drug interactions should also be investigated and not completely discarded. Although around five thousand clinical trials are ongoing worldwide for the development of new combination therapy, Palmer and Sorger, 2017 claims that most of the combination therapy used follows the
| Carrier composition | Therapeutics | Indication | Status | Targeting | Ref. |
|---------------------|--------------|------------|--------|-----------|------|
| Liposome based co-delivery of drugs against cancer | Topotecan + Vincristine | Brain cancer | In vivo | Passive | [18,211] |
| Liposome | Cisplatin + Doxorubicin | Vincristine | Various cancers | In vitro | Passive | [18] |
| Liposome | Cytarabine + Daunorubicin | Acute myeloid leukemia | Phase II | Passive | [18,212] |
| Liposome | Irinotecan + Floxuridine | Colorectal cancer | Phase II | Passive | [18,213,214] |
| The mixture of two Liposomes | Quercetin + Vincristine | Hormone- and TRZ insensitive breast cancer | In vivo | Passive | [18,215] |
| G5 PAMAM dendrimer (G5-Generation 5, PAMAM-poly(amidoamine)) | Antisense-miRNA21 + 5-fluorouracil | Glioblastoma | In vitro | Passive; miRNA overexpression | [18,218] |
| Aptamer-G4 PAMAM dendrimer conjugates (G4-Generation 4) | Unmethylated CpG-oligonucleotides + Doxorubicin | Prostate cancer | In vivo | Active; a single-strand DNA-A9 prostate-specific membrane antigen, RNA aptamer hybrid | [18,219] |
| Dendritic PEG H3N-PEG-dendrimer-(COOH) | Paclitaxel + alendronate | Cancer bone metastasis | In vivo | Both passive and active | [18,220] |
| RGDIK-G3 Poly-lysine dendrimer (G3-Generation 3) | Doxorubicin + siRNA | Globlastoma | In vitro | Active; αvβ3 integrin | [18,221] |
| Folate-G5 polypropyleneimine dendrimer with ethylenediamine core (G5-Generation 5) | Methotrexate all-trans-retinoic acid | Leukemia | In vitro | Active; folate receptor | [18,222] |
| Polymer based co-delivery of drugs against cancer | Lonidamine + Paclitaxel | Multiple drug resistant (MDR) breast cancer | In vitro | Active; EGFR | [18,223] |
| Methoxy PEG-PLGA | Doxorubicin + paclitaxel | Various cancers | In vitro | Passive | [18,223] |
| Methoxy PEG-PLA (PLA-poly(D,L lactic acid)) | Paclitaxel, Etoposide, or Docetaxel + 17-AAG | Various cancers | In vitro | Active; HSP90 | [18,224] |
| PEG-PLA | Combretastatin A4 + Doxorubicin | Various cancers | In vitro | Active; angiogenesis | [18,225] |
| PDMAEMA-PCL-PDMAEMA poly(N,N-dimethylamino-2-ethyl methacrylate)-polycaprolactone-poly(N,N-dimethylamino-2-ethyl methacrylate) | Paclitaxel + VEGF siRNA | Prostate cancer | In vitro | Active; VEGF | [18,226] |
| PEG-DSPE/PLGA | Combretastatin + Doxorubicin | Lung carcinoma | In vitro | Passive | [18,115] |
| PEG-PLA and PEG-DSPE/TPGS (TPGS-tocopheryl polyethylene glycol) | Paclitaxel + 17-AAG(HSP90 inhibitor) | Ovarian cancer | In vitro | Active; HSP90 | [18,227] |
| P(MDS-co-DES) poly(N-methyldeitheneamine sebacate)-co-[cholesterol oxocarboxylic ethyl methyl bis(ethylene ammonium bromide)] | Paclitaxel + Interleukin-12 | Breast cancer | In vivo | Active; Bcl-2 | [18,228] |
| PEG-b-PHSA PEG-block-poly(N-hexyl stearate l-aspartamide) | Doxorubicin + Wortmannin | Breast cancer | In vitro | Passive | [18,229] |
Table 11 Nanoparticle mediated co-delivery of drugs for cancer therapy (Continued)

| Carrier composition | Therapeutics | Indication | Status | Targeting | Ref. |
|---------------------|--------------|------------|--------|-----------|------|
| PLN formulation ((DG)n) (Polymer lipid hybrid nanoparticles (NP) co-loaded with DOX and GG918) | Doxorubicin + GG918 | Breast cancer | In vitro | Passive | [230] |
| PLGA | Vincristine + Verapamil | Hepatocellular carcinoma | In vitro | Passive | [18,231] |
| PLGA | Paclitaxel + Tariquidar | Breast cancer | In vitro | Passive | [173,232] |
| PLGA | Rapamycin + piperine | Breast cancer | In vitro | Passive | [173,234] |
| PACA polyalkylyanoacrylate outer shell, middle PLGA and inner PCL core (PCL- polycaprolactone; PCL- carboxylic functionalized PCL) | Doxorubicin + Cyclosporine A | Various cancers | In vitro | Passive | [173,235] |
| Bradykinin-potentiating peptide decorated chitosan nanoparticle | Bradykinin-potentiating peptide + bioreductively sensitive platinum (IV) compound which becomes cisplatin in intracellular reductive environment | Hepatocellular carcinoma | In vivo | Passive | [188,236] |

Polymeric micelles based co-delivery of drugs against cancer

| Carrier composition | Therapeutics | Indication | Status | Targeting | Ref. |
|---------------------|--------------|------------|--------|-----------|------|
| MPEG-b-P(LA-co-MCC) (MPEG-b-P(LA-co-MCC)) - methoxy poly(ethylene glycol)-block-poly(1-lactide-co-2-methyl-2-carboxypropylene carbonate) | Paclitaxel + Cisplatin | Cervical cancer | In vivo | Passive | [173,237] |
| PEG-PLL-P(Leu poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-leucine) | Docetaxel + Bcl-2 siRNA | Breast cancer | In vivo | Passive | [173,238] |
| PCL-b-P(PEGMA-co-AzPMA POEGMA- poly(EGMA); OEGMA- oligo(ethylene glycol) ethyl methacrylate; co-copolymer; AzPMA- 3-azidopropyl methacrylate) | Doxorubicin+ platinum(IV) | Cervical cancer and melanoma | In vitro | Passive | [173,239] |
| DA3 (deoxycholic acid-conjugated PEI) | Paclitaxel + XIAP siRNA | Colorectal cancer | In vivo | Passive | [173,240] |
| Self-assembled polymeric micelles | Paclitaxel + suramin siRNA | Ovarian cancer | In vivo | Passive | [173,241] |
| P–H/M (methoxy poly(ethylene glycol)-poly(caprolactone) micelles) | Paclitaxel + Honokiol | Breast cancer | In vivo | Passive | [173,242] |
| Crosslinked PEG-b-pAsp-b-pTyr | Docetaxel + Iminodamine | Breast cancer | In vivo | Passive | [173,243] |

Water-soluble polymer conjugate-based co-delivery of drugs against cancer

| Carrier composition | Therapeutics | Indication | Status | Targeting | Ref. |
|---------------------|--------------|------------|--------|-----------|------|
| HPMA copolymer | Doxorubicin + dexamethasone | General cancer | In vivo | Passive | [18,244] |
| HPMA copolymer | TNP-470 + Alectonrate | Bone metastasis | In vivo | Active; bone | [18,245] |
| HPMA copolymer | Paclitaxel + Alectonrate | Bone metastasis | In vivo | Active; bone | [18,118] |
| Branched PEG | Epirubicin + Nitric oxide | Colon cancer | In vivo | Passive | [18,248] |
| Branched PEG | Campthotecin + BH3 domain peptide | Ovarian primary tumor and metastatic malignant ascites | In vivo | Active; luteinizing hormone-releasing hormone | [18,249] |
| HPMA copolymer | Trastuzumab + PK166 | HER2 overexpressed breast cancer | In vitro | Active; HER2 | [18,250] |
| HPMA copolymer | 6.4 wt% gemcitabine + 5.7 wt% of Doxorubicin + 1.0 mol% tyrosinamide | Prostate cancer | In vivo | Passive | [173,251] |

Continued over
Table 11 Nanoparticle mediated co-delivery of drugs for cancer therapy (Continued)

| Carrier composition | Therapeutics | Indication          | Status  | Targeting                      | Ref. |
|---------------------|--------------|---------------------|---------|-------------------------------|------|
| Microsphere-based co-delivery of drugs against cancer |
| Double-walled microspheres, PLGA core surrounded by PLLA shell (PLLA- poly(L-lactic acid)) | Doxorubicin + Chitosan DNA p53 | Hepatocellular carcinoma | In vitro | Passive [173,252] |

| Carbon nanoparticle and carbon-based nanosystem based co-delivery of drugs against cancer |
| Nanodiamond | Paclitaxel + Cetuximab | Colorectal cancer | In vivo | Active, epidermal growth factor receptor positive cells | [173,253] |
| PEGylated lipid bilayer-wrapped nano-graphene oxide (GOLDR) | Doxorubicin + Rapamycin | Breast cancer | In vitro | Passive [173,254] |

| Metallic nanoparticle-based co-delivery of drugs against cancer |
| Silver nanoparticles (SN-AK-DOX) (SNs- silver nanoparticles; AK- sanazole) | Sanazole + Doxorubicin | Lymphoma | In vivo | Active, hypoxic cells | [173,255] |
| Gold nanoparticles | Doxorubicin + +Cisplatin, | Hepatocellular carcinoma | In vitro | Passive | [173,256] |

independent action model and provide therapeutic benefit due to patient-to-patient variability rather than additive or synergistic drug interactions [265,266].

One of the key challenges in developing nanoparticle-based targeted therapy is the issue of toxicity of treatment combinations. Seemingly rationally developed and assumed to be safe combination therapy in preclinical model may fail in clinical trials due to toxicity, especially in the case of synergistic drugs which can lead to synergistic toxicity as well due to similar mechanism of action or due to auto immune response of healthy tissue [169]. Mathematical modeling has been helpful in predicting toxicity in pre-clinical trials and can be used as an efficient tool for predicting the toxicity of drug combinations in a patient-specific manner [169]. Toxicity of the drug nanocarrier also needs to be considered. Another hurdle in the success of combinatorial nanotherapeutics to be translated into clinics is the lack of patients who are interested in participating in clinical trials. Approximately 40% of cancer trials fail due to the scarcity of patients [169]. Cancer is a highly heterogeneous disease and cell type population in a particular type of malignant tumor varies from patient to patient. For clinical trials to have higher success rates, efficient biomarkers need to be identified first. Additionally, clinical trials should be performed on patients with a similar level of biomarker expression. But due to the lack of patients enrolled in a clinical trial, such arrangements are not possible. Due to the insufficiency of suitable patients for performing clinical trials, precise preclinical models need to be developed. Researchers need to look beyond immune-competent mice model and use patient-derived xenograft in vivo models, humanized mouse models and patient-derived organoids for a greater chance of success in clinical trials and such models can also be used as an efficient tool for predicting the toxicity of drug combinations in a patient specific manner [169].

**Nanomedicine and combination nanomedicine for cancer immunotherapy**

Immunotherapy is a monumental breakthrough recently included in the existing therapeutic armamentarium against cancer. It utilizes body's own immune system to fight cancer. William Coley, known as the father of immunotherapy, first attempted to treat cancer utilizing the immune system. However, this field got attention when James P. Allison and Tasuku Honjo got the Nobel prize for cancer immunotherapy in the year 2018. Judy Perkins having stage IV metastatic breast cancer, was the first lady to be cured successfully by immunotherapy [267]. Current cancer immunotherapy comprises cytokine therapy, antibody-based therapy and adoptive cell therapy. However, complex tumor microenvironment limits the efficacy of immunotherapy. In the tumor microenvironment, tumor cells can polarize tumor associated macrophages (TAM) toward pro-tumorigenic M2 macrophages while decreasing antitumor M1 macrophages to facilitate tumor progression. Moreover, cancer cells help to activate immune checkpoints leaving the T cells in a state of anergy (lack of responsiveness to an antigen). Cancer immunotherapy inhibits immune checkpoints to overcome the T-cell anergy, thereby its activation against cancer. Ipilimumab inhibits the
cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) checkpoint in T cells leading to its activation. Similarly, programmed cell death protein 1 (PD-1) in T cells is inhibited by FDA-approved anti PD-1 antibody pembrolizumab and nivolumab. Cancer cells overexpress the immune checkpoint protein programmed death-ligand 1 (PD-L1). The PD-L1 inhibiting antibodies atezolizumab, avelumab, durvalumab are also approved by FDA [268]. These antibodies block the inhibitory signal induced by interaction of PD-1 of T cell to PD-L1 of the cancer cell. Multiple colony stimulating factor receptor 1 (CSF-1R) inhibitors are currently in clinical trials for their ability to polarize tumor associated macrophages to anti-tumorigenic M1 phenotype [13].

Peptide-based drugs/vaccines can hugely advance cancer immunotherapy. Peptides can be designed in a more rationalized manner to target desired molecule of tumor or the tumor microenvironment. Yin et al. have designed a peptide (IQIREKRCGOQDEERVRRCEKGERQNYCHYVHKEGNCYVCGIICL) mimicking the native structure of the PD-1 molecule, which inhibited the interaction between PD-L1 of cancer cells and PD-1 of immune cells. This peptide was developed as a potent drug for cancer immunotherapy [269]. Hazama et al. also developed a peptide-based macrocyclic peptide (c[Ac-DYRYSAVYSIHPSWC]G) inhibiting the interaction between cluster of differentiation 47 (CD47) of cancer cell and signal regulatory protein α (SIRPα) of macrophages and showed its in vivo efficacy [270]. Peptide-based cancer vaccines can specifically stimulate cancer specific T cell response [271]. Peptide-based (9 amino acid residues) vaccine GP2 (IISAVVGIL) is currently in phase 2 clinical trial against breast cancer [272]. Several other examples of peptide vaccines combined with other drugs are highlighted in Table 10.

Researchers have reported a number of combinatorial approaches where immunotherapeutic drugs are combined with the conventional cancer therapeutics such as chemotherapy, RNAi therapy, photothermal, photodynamic and radiotherapy as described in Tables 12-14 and Figure 11.

Chemotherapy with immunotherapy
Combination chemotherapy with cancer immunotherapy is a wide area of interest. In phase III clinical trial, albumin nanoparticle bound chemotherapeutic drug paclitaxel (Abraxane®) combined with atezolizumab (Tecentriq®; FDA approved antibody of PD-L1) has recently demonstrated its efficacy in patients with advanced triple-negative breast cancer (TNBC) [22,298]. However, some patients showed grade 3 (moderate to severe) or grade 4 (life threatening symptoms) immune related adverse events [298]. Hence, combination of nanoparticle-mediated chemo-immunotherapy may facilitate targeted and localized delivery to increase the therapeutic index, reduce off-target toxicity and incidences of immune related adverse events. Tables 12 shows some examples of preclinical studies on combination of nanoparticle mediated chemotherapy and immunotherapy.

RNAi therapy with immunotherapy
RNA interference (RNAi) therapy with siRNA, microRNA (miRNA) and short hairpin RNA (shRNA) is utilized to silence genes of specific signaling molecules, cytokines and chemokines. However, this therapy possesses certain limitations like rapid degradation of RNA-based drugs in circulation due to presence of nucleases, renal clearance, poor cellular uptake because of anionic nature, etc [299]. Therefore, nanoparticles have been used to circumvent such barriers. Gene therapy has been utilized in targeting immune checkpoints like PD-1-PD-L1 pathway [300]. Also, these can be used with other cancer treatment modalities to induce immune stimulation against cancer. Few examples are given in Table 13 where combination nanomedicine having immunotherapeutic drugs showed enhanced efficacy.

Photothermal, photodynamic and radiotherapy with immunotherapy
Photothermal, photodynamic and radiotherapies are also used in combination with immunotherapy. In photothermal therapy, cancer cells can be destroyed and eliminated from the tumor tissues at 40–44°C temperature due to DNA damage, protein denaturation and disruption of cellular membrane [20]. However, it requires high temperature for complete cell death, thus large tumors are prone to relapse. Thus combining photothermal therapy with immune-stimulating agents and nanoparticles can synergistically induce anti-tumor efficacy for the treatment of large established tumors and distant metastases.

Photodynamic therapy comprising combination of light with photosensitizers leads to the generation of reactive oxygen species (ROS) and subsequently damage of subcellular organelles [301]. However, as a monotherapy, it does not efficiently regress the tumor in an immunosuppressive tumor microenvironment [20]. It induces immunosuppression by the release of immunosuppressive cytokines. It provokes damage to the normal cells by releasing the
Table 12 Combination nanomedicine having immunotherapeutic drugs with chemotherapeutic drugs

| Chemotherapeutic drugs | Immunotherapeutic drugs | Nanoparticle delivery system | Cancer Type | Outcome | Ref. |
|------------------------|------------------------|-----------------------------|-------------|---------|------|
| Doxorubicin            | Anti-PD-1 antibody     | Synthetic high-density lipoprotein (shDL) like nanodiscs loaded with DOX | CT26 and MC38 mouse colon carcinoma | Induced strong anticancer immunity and sensitized tumors to immune checkpoint blockade | [273] |
| Doxorubicin            | Cytosine–phosphate–guanosine oligonucleotides (CpG-ONT) (Immune-stimulating agent) | An RNA aptamer (recognizing a prostate-specific membrane antigen (PSMA)) bioconjugated with a dendrimer attached with Cpg-ONTs loaded with DOX | In vivo and in vivo models of prostate cancer (22RV1) | Showed excellent antitumor efficacy, immune stimulation and target specificity | [219] |
| Paclitaxel             | Toll-like receptor-7 (TLR-7) agonist-imiquimod | Poly (γ-glutamic acid) (γ-PGA) micro-dispersion system of drugs | In vitro and in vivo mouse melanoma (B16-F10) | Showed robust immunogenic tumor cell death followed by inhibition of secondary tumors also | [274] |
| Paclitaxel             | TLR-4 agonist bacterial endotoxin Lipopolysaccharide (LPS) | Co-encapsulation by PLGA-based nanoparticle | In vitro and in vivo murine melanoma model (B16-F10) | Tumor volume was found 40% less and immune activation was observed | [275] |
| Paclitaxel             | Cytosine–phosphate–guanosine oligodeoxynucleotides (CpG ODNs) and IL-10 siRNA (Immune-stimulating agents) | PLGA-based nanoparticles | Murine melanoma model (B16-F10) | Efficiently inhibited tumor growth and increased the animal survival rate | [276] |
| Cisplatin              | Cytosine–phosphate–guanosine (CpG) (Immune-stimulating agent) | Liposome | Murine melanoma model (B16-F10) | Strong synergistic effect which increased apoptosis and reduced tumor growth | [277] |
| Mitoxantrone treated   | Anti-PD-1 antibody      | Hyaluronic acid–cationic lipid nanoparticle was loaded with CpG | Murine model of melanoma and colon carcinoma (B16-F10-OVA and CT26) | Complete tumor regression in almost 78% of CT26 tumor-bearing mice and long-term immunity against tumor recurrence | [278] |
| CT26 cancer cells      | Immune checkpoint inhibitor antibodies anti-CTLA-4 and anti-OX40 | PLGA-based microparticles | Mouse lymphoma (EL4, E20) and mouse melanoma (B16-F1-LUC) models | Generated systemic immune responses that suppressed injected and distant tumors in a murine B lymphoma model, leading to tumor-free mice Reduced tumor burdens | [279] |
| Doxorubicin            | Immunotherapeutic agent interferon-γ (IFN-γ) | PLGA-based thermosensitive nanoparticle | Murine melanoma model (B16-F10) | Prolonged circulation time, sustained drug release, excellent synergistic antitumor efficiency against B16F10 tumor bearing mice | [280] |
| Paclitaxel             | Interleukin-2           | Hydroxypropyl-β- cycloexetin acrylate and two opposite charged chitosan derivatives based nanogels coated by RBC membrane | Murine melanoma model (B16-F10) | Enhanced antitumor activity with improved drug penetration and increased antitumor immunity | [281] |
| Doxorubicin (DOX),     | Interleukin-2           | Lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) | Murine melanoma model (B16-F10) | Significant tumor growth and metastasis inhibition | [282] |

self-antigens [302]. Thus, to balance the immunosuppressive effects of mono-photodynamic therapy, immunotherapy needs to be combined with it.

In radiotherapy, high energy ionizing radiation such as X-rays are utilized to cause free radical generation mediated DNA and cellular damage leading to cellular death [303]. However, radiation therapy helps to develop anticancer therapy, its solo use promotes immunosuppressive environment around tumor by recruiting immunosuppressive T\textsubscript{reg} cells [304]. It causes increased production of immune-inhibitory molecules such as PD-L1 and transforming growth factor-β (TGF\textbeta) [305]. Thus, to overcome these problems of radio-monotherapy, combination of radiotherapy with immunotherapy is implicated. Some examples are given in Table 14.
Next-generation combination nanomedicine for immunotherapy

Immune checkpoint inhibitors were initially used in combination with other conventional chemotherapeutic drugs or radiotherapy (Tables 12-14) to potentiate the tumor regression. At present, nanomedicines for immunotherapy combines mechanistically inspired drug which can demonstrate a synergistic effect. Sengupta and co-workers have designed a supramolecular bifunctional nanomedicine comprising amphiphiles which inhibits interaction of CD47 of cancer cell and SIRPα of macrophages and simultaneously the interaction of macrophage colony stimulating factor (MCSF) and colony stimulating factor 1 receptor (CSF-1R). This nanomedicine increases the M2 to M1 repolarization within the tumor microenvironment and improves the anticancer and antimetastatic efficacy in melanoma and breast cancer model [306]. Mitragotri and co-workers designed a class of phagocytosis-resistant discoidal particles containing interferon-γ (IFN-γ). These particles showed efficient adherence to macrophages and directed their polarization toward anti-tumor M1 phenotype in murine breast cancer model [307]. Other such combinations are described in the next section.

Combination immunotherapy with signaling pathways inhibitors

Next-generation cancer immunotherapy needs to be patient-specific to enhance its antitumor efficacy. Immunotherapeutic drugs can be combined with signaling pathway inhibitors for better synergistic outcomes and to amplify the efficacy of personalized medicine [308]. MEK inhibitors are used in combination with PD-L1 antibodies as MEK inhibition causes up-regulation of PD-L1 in cancer cells. In cancer, the dysregulated PI3K-AKT pathway also regulates the PD-L1 expression [309]. Kulkarni et al. designed a nanomedicine combining PD1-PDL1 immune checkpoint inhibitor with kinase (MEK and PI3K) inhibitors for enhanced anti-tumor efficacy [81]. It has also been reported that second generation anti-histaminic drugs like cetirizine, etc., in combination with immunotherapy, have improved the anticancer efficacy [310].

Combination immunotherapy with GPCR inhibitor

Combination of G-protein-coupled receptor (GPCR) inhibitors and immune checkpoint inhibitors can amplify antitumor efficacy. CXCR4, a GPCR, is overexpressed in cancer cells which mediates cell proliferation, tumor growth, metastasis and tumor relapse [311]. CXCL12, the chemokine binding to the CXCR4, is secreted from fibroblast cells in the tumor microenvironment. CXCL12/CXCR4 axis is another molecular target for cancer treatment as this axis leads to an immunosuppressive tumor microenvironment. Thus, combining plerixafor (AMD3100; CXCR4 inhibitor) with immune checkpoint inhibitor anti-PDL1 antibody showed decreased tumor volume [312].
Table 14 Combination nanomedicine of immunotherapeutic drugs with photothermal, photodynamic and radiotherapy

| Photothermal/photodynamic/radiotherapy | Immunotherapeutic drugs | Nanoparticle delivery system | Cancer | Outcome | Ref. |
|--------------------------------------|-------------------------|-----------------------------|--------|---------|------|
| Photothermal ablation (near infrared light) | Immunoadjuvants oligodeoxynucleotides containing the cytosineguanine (CpG) motifs | Chitosan coated hollow Copper Sulfide nanoparticles | Murine breast cancer model (EMT6-OVA, EMT6) | Combined photothermal immunotherapy is more effective than immunotherapy/photothermal therapy alone in mouse breast cancer model | [288] |
| Photothermal ablation (near infrared laser) | Adoptive T cell therapy | Gold nanoshell | Murine melanoma (B16-F10) | Prevents primary tumor recurrence post-ablation, inhibited tumor growth at distant sites, and abrogated the outgrowth of lung metastases | [289] |
| Photothermal ablation | Anti-CTLA-4 antibody | Single-walled carbon nanotube | Murine model of breast cancer (4T1) | Tumor metastasis prevented | [290] |
| Photothermal ablation | Gold nanostar | Anti-PDL1 antibody | Mouse bladder cancer (MB49) | Both primary and distant tumors were safely eradicated | [291] |
| Photosensitizer pyropheophorbide-lipid conjugate (pyrolipid) in the shell and oxaliplatin in the core | Anti PD-L1 antibody | Nanoscale coordination polymer (NCP) core-shell nanoparticles | Murine colorectal tumor model (CT26 and MC38) | This combination causes regression of both primary and distant tumors via induction of strong cancer specific immune response | [292] |
| Photosensitizer pyrolipid (ZnP@pyro) | Anti PD-L1 antibody | Zn-pyrophosphate (ZnP) nanoparticles | Murine breast cancer model (4T1) | Complete eradication of primary and distant tumors via systemic cancer specific cytotoxic T-cell response | [293] |
| Chlorin e6 (Ce6), a photosensitizer and imiquimod (R837), a Toll-like-receptor-7 agonist | Anti-CTLA-4 antibody | Upconversion nanoparticles (UCNPs) | Murine colon carcinoma (CT26) | Eliminates NIR laser exposed tumors but causes strong anticancer immunity to inhibit distant tumors also | [294] |
| TBC-Hf (derived from tetra(pbenzoato)chlorin and Hf) enabled photodynamic therapy | Small-molecule inhibitor of indoleamine 2,3-dioxygenase (IDO) | Chlorin-based nanoscale metal–organic framework (nMOF) | Murine colorectal models (CT26 and MC38) | Effective local and distant tumor rejection in colorectal cancer models | [295] |
| Radiation therapy | Cowpea-mosaic virus | Cowpea-mosaic virus nanoparticle | Murine ovarian cancer (ID8- Defb29/Vegf-A-Luc cells) | Resulted in improved tumor growth delay and an increase in tumor infiltrating lymphocytes (TILs) | [296] |
| Radiotherapy | Small molecule based indoleamine 2,3-dioxygenase (IDO) inhibitor | Hafnium (Hf)-based nanoparticle | Mouse models of breast and colorectal cancer | Eradication of local and distal tumors in vivo models | [297] |

Combination immunotherapy with epigenetic drugs

Epigenetic drugs can potentiate combination immunotherapy [313]. DNA hypomethylating agent 5-aza-2’-deoxycytidine (5-AZA-CdR) (a DNA methyltransferase inhibitor, DNMTi) combined with an anti-CTLA-4 monoclonal antibody showed enhanced antitumor efficacy in murine model of breast cancer [314]. In Phase Ib clinical trial, the epigenetic drug guadecitabine was combined with ipilimumab (anti-CTLA-4 antibody) for patients having stage III/IV melanoma. The DNA hypomethylating drugs cause upregulation of genes CD274, PDCD1LG2, and CTLA-4 in the patients where resistance has developed. Currently, a PEG-based nanoparticle system was utilized to deliver plasmid-encoding shPD-L1 (this plasmid down-regulated expression of PD-L1 protein of cancer cells) in combination with Zebularine (a DNMTi, causing overexpression of major histocompatibility complex I [MHC-I] expression). This combination can effectively initiate anticancer immunity and prevent tumor relapse by a strong anticancer memory [315].
Figure 11. Next-generation combination nanomedicine for immunotherapy

(A) CD47 (cluster of differentiation 47; a transmembrane protein) is overexpressed on cancer cells and binds to SIRPα (signal regulatory protein α; a regulatory membrane glycoprotein) on immune cells to inactivate immune cells and escape immune surveillance. Similarly, MCSF (macrophage colony stimulating factor; a secretory protein) released from cancer cells which binds to CSF-1R (colony stimulating factor 1 receptor; a transmembrane protein) on immune cells and inactivates immune cells. A supramolecular nanoparticle, comprising anti-SIRPα antibody with a small molecule inhibitor (BLZ-945) of CSF-1R inhibits both the signaling axes simultaneously and shows anti-tumor immune response. (B) Nanoparticle having immune checkpoint inhibitor and a small molecule-based kinase inhibitor causes targeted disruption of kinase signaling only in cancer cells while keeping the PI3K and MAPK pathways of immune cells untouched. This strategy enables inhibition of kinase signaling. (C) Chemokine CXCL12 (C-X-C motif chemokine ligand 12), secreted from fibroblast cells binds to CXCR4 (C-X-C chemokine receptor 4), a G-protein-coupled receptor from cancer cells and promotes immunosuppressive tumor microenvironment. Combination immunotherapy with inhibitors of CXCR4/CXCL12 axis can amplify the antitumor efficacy. (D) combination of epigenetic inhibitor (Zebularine, a DNMTi) with immune checkpoint inhibitor of PD-L1 can potentiate combination immunotherapy.

Limitations and future prospect of nanoparticle-mediated combination immunotherapy

Currently, immunotherapy is the latest approach that has emerged in finding a cure for cancer. However, only immunotherapy is insufficient to eradicate tumors due to: (1) lack of specificity and systemic toxicity, (2) low patient response rate, (3) variable immune contexture of patients, etc., (4) impaired immune function and antibody activity due to the acidic tumor microenvironment (Warburg effect), (5) divergent immune pattern of different organs, (6) development of resistance against immunotherapy, (7) autoimmune adverse effect generation by immune checkpoint blockade, (8) increased immune suppression with aging and (9) huge cost [316–318].

To advance the area of cancer immunotherapy in near future, toxicity issues associated with immunotherapy need to be addressed. Since cancer is a highly heterogeneous disease, nanocarrier encapsulated precision combinatorial immunotherapy will hold a great prospect in future cancer therapy. Tumor heterogeneity can be explored by the
determination of biomarkers via genomic analysis of circulating cancer cells. Next-generation sequencing can be deployed to explore immunogenicity of mutated genes. These data along with resources like cBioPortal, Project Genie can be utilized in designing patient-specific immunotherapy in an effective and safer manner. Immunotherapy can be further boosted by utilizing combinatorial approaches. This would require identification of optimal dosing and delivering the same dose to the tumor site. This can be achieved by ratiometric dosing as described earlier. Mono anti-PD-1 therapy often causes compensatory activation of other checkpoints (e.g., CTLA-4), leading to immunosuppression [319]. Thus, simultaneous blocking of inter-related checkpoints is necessary to design effective combinatorial immunotherapy. The gut microbiome or blood supply to the tumor site can also alter responses to cancer immunotherapy by indirectly modifying tumor microenvironment [320]. Hence modulating these factors can help combating resistance to immunotherapy. Furthermore, antagonizing low pH of tumor microenvironment by acidity modulating drugs (proton-pump inhibitors) might act as a possible choice to overcome tumor resistance, potentiating the existing immunotherapy [318]. Thus, optimizing the current immunotherapy with personalized combinatorial nanomedicines can advance the development of next-generation cancer nano-immunotherapy.

Conclusion and future direction
The challenges of next-generation nanoparticle mediated multicomponent combination therapy and combination immunotherapy need to amplify the therapeutic potential by providing the enhanced stability of cancer drugs in biologically active form, reducing toxicity related issues, overcoming immunosuppression and preferentially accumulating at the tumor site. Due to lack of fenestrated or discontinuous endothelium, effective delivery of clinically safe nanomedicine to less accessible tissues remains a considerable challenge. To achieve clinically potential, optimized nanoparticle designing, innovation in designing the mechanistically inspired nanoparticle, targeting specific metastatic foci, their delivery process and in vivo biodistribution based on structure and activity need detailed understanding. Integrating cancer biology and anti-metastatic nanotechnology, new strategies need to be engineered considering the biological mechanisms of various stages of metastasis. Tumor microenvironment specific targeted therapeutic intervention is desirable to improve the outcome. New guidelines need to be developed about engineering multicomponent combination therapy and it requires extensive studies on various classes of drug combinations, our understanding about inter-drug interactions for such cases, spatio-temporal release of anticancer drugs, nonspecific activation of the immune system by such multicomponent combination nanomedicine, diversity of metastatic foci, diversity of organ environment and delivery of biologically active multicomponent nanomedicine at the epicentre of solid tumor. Such therapeutics need to be developed by integrating clinical trials with an adequate number of patients having similar biomarker expression and the development of better pre-clinical models. Next-generation multifunctional cancer nanomedicine and nanoparticle mediated combination immunotherapy having mechanistically rational therapeutic combinations need to promote “multi-targeted therapy” by disrupting the adaptive chemoresistance and potentiating the effect of therapeutic combinations. Integrating proteomics data of patient samples, combination nanotherapy and immune-oncology, one may develop highly effective precision nanomedicine.

Competing Interests
The authors declare the following competing financial interests: We have filed patents on peptide based siRNA transporters (application no: 201931001645, 201731040460) and peptide based cancer drugs (application no: 201731046166). R.S.R., Prof. Dhananjay Bhattacharyya (D.B.), A.M.M., Dr Abhijit Biswas (A.B.), K.C. and Dr Sanchita Mukherjee (S.M.) are inventors in the patent application no: 201931001645. R.S.R., D.B., Dr Chiranjit Dutta, A.B., K.C., S.M. and Paramita Gayen are inventors in the patent application no: 201731046166. Hence authorship of the current manuscript is a conflict of interest.

Funding
RSR thanks SERB-Power fellowship grant [grant number SPF/2021/000024]; DST SERB [grant number EMR/2016/003829]; and DBT Nanobiotechnology [grant number BT/PR22086/NNT/28/1222/2017] for funding.

Author Contribution
Dr Kasturee Chakraborty, Archana Tripathi, Sukumar Mishra, Argha Mario Mallick and Dr Rituparna Sinha Roy designed and drafted this review article. All authors had read and approved the final manuscript.

Acknowledgements
R.S.R. thanks SERB-Power fellowship. K.C. and S.M. thank CSIR for fellowship, A.M.M. thanks CSIR and DBT Nanobiotechnology (BT/PR27059/NNT/28/1543/2017) for fellowship and A.T. thanks IISER Kolkata for Ph.D. fellowship.
Abbreviations
CD47, cluster of differentiation 47; CSF-1R, colony stimulating factor 1 receptor; CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; DNMTi, DNA methyltransferase inhibitor; GPCR, G-protein-coupled receptor; IFN-γ, interferon-γ; M-CSF, macrophage colony stimulating factor; MHC-I, major histocompatibility complex I; NIR, near infrared; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SIRPα, signal regulatory protein α; TAM, tumor associated macrophages; TGFβ, transforming growth factor-β.

References
1. Sung, H., Ferlaj, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249, https://doi.org/10.3322/caac.21660
2. Riis, M. (2020) Modern surgical treatment of breast cancer. Ann. Med. Surg. 56, 95–107, https://doi.org/10.1016/j.amsu.2020.06.016
3. Yang, T.J. and Ho, A.Y. (2013) Radiation therapy in the management of breast cancer. Surg. Clin. North Am. 93, 455–471, https://doi.org/10.1016/j.suc.2013.01.002
4. Taghian, A.G. and Powell, S.N. (1999) The role of radiation therapy for primary breast cancer. Surg. Clin. North Am. 79, 1091–1115, https://doi.org/10.1016/S0039-6109(05)70063-3
5. Moo, T.-A., Sanford, R., Dang, C. and Morrow, M. (2018) Overview of breast cancer therapy. PET Clin. 13, 339–354, https://doi.org/10.1016/j.petcp.2018.02.006
6. Hassan, M., Ansari, J., Spooner, D. and Hussain, S. (2010) Chemotherapy for breast cancer. Oncol. Rep. 24, 1121–1131, https://doi.org/10.3892/or.00000963
7. Banerjee, D. and Sengupta, S. (2011) Nanoparticles in cancer chemotherapy. Prog. Mol. Biol. Transl. Sci. 104, 489–507, https://doi.org/10.1016/B978-0-12-416020-0.00012-7
8. Tinkle, S., McNeil, S.E., Mühlbach, S., Bawa, R., Borchard, G., Barenholz, Y. et al. (2014) Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci. 1313, 35–56, https://doi.org/10.1111/nyas.12403
9. Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M. and Rizzolio, F. (2019) The history of nanoscience and nanotechnology: from chemical–physical applications to nanomedicine. Molecules 25, 112, https://doi.org/10.3390/molecules25011012
10. Blanco, E., Shen, H. and Ferrari, M. (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951, https://doi.org/10.1038/nbt.3330
11. Davis, M.E., Chen, Z. and Shin, D.M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discovery 7, 771–782, https://doi.org/10.1038/nrd2614
12. Aslan, B., Ozpolat, B., Sood, A.K. and Lopez-Berestein, G. (2013) Nanotechnology in cancer therapy. J. Drug Target. 21, 904–913, https://doi.org/10.3109/1061186X.2013.837469
13. Sengupta, S. (2017) Cancer nanomedicine: lessons for immuno-oncology. Trends Cancer 3, 551–560, https://doi.org/10.1016/j.trecan.2017.06.006
14. Bartlett, D.W. and Davis, M.E. (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18, 456–468, https://doi.org/10.1021/bc0603539
15. Song, E., Zhu, P., Lee, S.-K., Kussman, S., Dykxhoorn, D.M. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709–717, https://doi.org/10.1038/nbt1101
16. Edirwickerma, A. and Saltzman, W.M. (2015) Nanotherapy for cancer: targeting and multifunctionality in the future of cancer therapeutics. ACS Biomater. Sci. Eng. 1, 64–78, https://doi.org/10.1021/ab500084g
17. Derakhshanbed, K. and Azandaryani, A.H. (2016) Active-targeted nanotherapy as smart cancer treatment. Smart Drug Deliv. Syst. 91–116, http://dx.doi.org/10.7572/61791
18. Lee, J.H. and Nan, A. (2012) Combination drug delivery approaches for metastatic breast cancer. J. Drug Deliv. 2012, 915375, https://doi.org/10.1155/2012/915375
19. Wong, J.K., Mohseni, R., Hamidieh, A.A., MacLaren, R.E., Habib, N. and Seifalian, A.M. (2017) Will nanotechnology bring new hope for gene delivery? Nanomedicine 35, 434–451, https://doi.org/10.1016/j.nano.2016.12.009
20. Nam, J., Son, S., Park, K.S., Zou, W., Shea, L.D. and Moon, J.J. (2019) Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 389–414, https://doi.org/10.1038/s41578-019-0108-1
21. Baskar, R., Lee, K.A., Yeo, R. and Yeoh, K.-W. (2012) Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci. 9, 193, https://doi.org/10.7150/ijms.3635
22. Yu, H.-J. and De Geest, B.G. (2020) Nanomedicine and cancer immunotherapy, vol. 41, Nature Publishing Group
23. Van Hong Nguyen, B.-J.L. (2017) Protein corona: a new approach for nanomedicine design. Int. J. Nanomed. 12, 3137, https://doi.org/10.2147/IJNN.S129300
24. Wilhelm, S., Tavares, A.J., Daf, O., Ohta, S., Audet, J., Dvorak, H.F. et al. (2016) Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 1–12, https://doi.org/10.1038/natrevmats.2016.14
25. Corbo, C., Molinaro, R., Parodi, A., Toledano Furman, N.E., Salvatore, F. et al. (2016) The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine 11, 81–100, https://doi.org/10.2217/nmm.15.188
26. Banerjee, S.S., Aher, N., Patil, R. and Khundale, J. (2012) Poly (ethylene glycol)-prodrug conjugates: concept, design, and applications. J. Drug Deliv. 2012, 103973, https://doi.org/10.1155/2012/103973
27. Suh, J.S., Xu, O., Kim, N., Hanes, J. and Ensign, L.M. (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug. Deliv. Res. 99, 28–51, https://doi.org/10.1016/j.addr.2015.09.012
28 Basu, S., Chaudhuri, P. and Sengupta, S. (2009) Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle 8, 3480–3487, https://doi.org/10.4161/cc.8.21.9851

29 Athia, M.F., Anton, N., Wallyn, J., Omran, Z. and Vandamme, T.F. (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J. Pharm. Pharmacol. 71, 1185–1198, https://doi.org/10.1111/jphp.13098

30 Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumortropic accumulation of proteins and the antitumor agent smac. Cancer Res. 46, 6387–6392

31 Sutton, D., Nasonkla, N., Blanco, E. and Gao, J. (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 24, 1029–1046, https://doi.org/10.1007/s11095-006-9223-y

32 Sparreboom, A., Scripture, C.D., Trieu, V., Williams, P.J., De, T., Yang, A. et al. (2005) Comparative preclinical and clinical pharmacokinetics of a cemophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11, 4136–4143, https://doi.org/10.1158/1078-0432.CCR-04-2299

33 Boddy, A.V., Plummer, E.R., Todd, R., Sludden, J., Griffin, M., Robson, L. et al. (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 11, 7834–7840, https://doi.org/10.1158/1078-0432.CCR-05-0803

34 Kraut, E.H., Fishman, M.N., Lorusso, P.M., Gordon, M.S., Rubin, E.H., Haas, A. et al. (2005) Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacokinetics, pharmacodynamics, and tumor response. J. Clin. Oncol. 23, 2017–2017, https://doi.org/10.1200/jco.2005.23.16.suppl.2017

35 Daud, A., Garrett, C., Simon, G., Munster, P., Sullivan, D., Stromatt, S. et al. (2006) Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors. J. Clin. Oncol. 24, 2015–2015, https://doi.org/10.1200/jco.2006.24.18.suppl.2015

36 Dong, X., Sun, Z., Wang, X. and Leng, X. (2017) An innovative MWCNTs/DOX/TC nanosystem for chemo-photothermal combination therapy of cancer. J. Mater. Chem. B 5, 14078–14078, https://doi.org/10.1039/c7tb00280b

37 Gao, F., Zhang, Z., Bu, H., Huang, Y., Gao, Z., Shen, J. et al. (2011) Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J. Control. Release 149, 168–174, https://doi.org/10.1016/j.jconrel.2010.10.013

38 Ganassin, R., Merker, C., Rodrigues, M.C., Guimarães, N.F., Sodrê, C.S.C., Ferreira, Q.d.S. et al. (2018) Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. Artificial Cells Nanomed. Biotechnol. 46, 2002–2012

39 Sun, W., Jiang, T., Lu, Y., Reiff, M., Mo, R. and Gu, Z. (2014) Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J. Am. Chem. Soc. 136, 14722–14725, https://doi.org/10.1021/ja5088024

40 Dong, X., Sun, Z., Wang, X. and Leng, X. (2017) An innovative MWNTs/DOX/TC nanosystem for chemo-photothermal combination therapy of cancer. Nanomed. Nanotechnol. Biol. Med. 13, 2221–2280, https://doi.org/10.1016/j.nano.2017.07.002

41 Muhamad, N., Plengsuriyakarn, T. and Na-Bangchang, K. (2018) Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int. J. Nanomed. 13, 3921, https://doi.org/10.2147/ijn.s165210

42 Gray, B.P. and Brown, K.C. (2014) Combinatorial peptide libraries: mining for cell-binding peptides. Chem. Rev. 114, 1020–1081, https://doi.org/10.1021/cr400166n

43 Bross, P.F., Beltz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L. et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496

44 Kawakami, K., Nakajima, O., Morishita, R. and Nagai, R. (2006) Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. Sci. World J. 6, 781–790, https://doi.org/10.1100/tbw.2006.162

45 Allen, T.M. (2002) Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750–763, https://doi.org/10.1038/nrc903

46 Duncan, R. (2006) Polymer conjugates as anticancer nanomedicines. Clin. Cancer Res. 12, 688–701, https://doi.org/10.1158/1078-0432.CCR-05-0803

47 Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y. et al. (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15, 517–525, https://doi.org/10.1093/annonc/mdh092

48 Phan, A., Nakamoto, C., Adinin, R., Wood, L., Xiong, H., Matsuno, K. et al. (2007) Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. AACR 6, C115

49 Tang, W., Lalezar, J., June, C., Tebas, P., Lee, G., Giedlin, M. et al. (2012) S1. Results of a Phase I Trial of SGT-53: A Systemically Administered, Size matters: arginine-derived peptides targeting the PSMA receptor can efficiently complex but not transfect siRNA. Proc. Natl. Acad. Sci. 104, 5715–5721, https://doi.org/10.1073/pnas.0701458104

50 Aulio, K.A., Dreicer, R., Anderson, J., Garcia, J.A., Alva, A., Hart, L.L. et al. (2018) Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 4, 1344–1351, https://doi.org/10.1001/jamaoncol.2018.2168

51 Culltra, C.N., Shah, S., Antuono, G., Heller, C.J., Ramos, J.A., Samuni, U. et al. (2019) Size matters: arginine-derived peptides targeting the PSMA receptor can efficiently complex but not transfect siRNA. Mol. Therapy-Nucleic Acids 18, 863–870, https://doi.org/10.1016/j.omtn.2019.01.013

52 Lee, J.H., Engler, J.A., Collawn, J.F. and Moore, B.A. (2001) Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem. 268, 2004–2012, https://doi.org/10.1046/j.1432-1377.2001.02073.x

53 Wurm, D.J., Els-Heindl, S. and Beck-Sickinger, A.G. (2020) Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates. Pept. Sci. 112, e24171, https://doi.org/10.1002/pep2.24171

54 Sun, L.-C., ;, H. and Coy, D. (2011) Somatostatin receptor-targeted anti-cancer therapy. Curr. Drug Deliv. 8, 2–10, https://doi.org/10.2174/156720111793663633
86 Biswas, A., Chakraborty, K., Dutta, C., Mukherjee, S., Gayen, P., Jan, S. et al. (2019) Engineered histidine-enriched facial Lipopeptides for enhanced intracellular delivery of functional siRNA to triple negative breast Cancer cells. ACS Appl. Mater. Interfaces 11, 4719–4736, https://doi.org/10.1021/acsami.8b13794
87 Kim, B.Y., Rutka, J.T. and Chan, W.C. (2010) Nanomedicine. N. Engl. J. Med. 363, 2434–2443, https://doi.org/10.1056/NEJMra0912273
88 Kulkarni, A.A., Vijaykumar, V.E., Natarajan, S.K., Sengupta, S. and Sabbsieti, V.S. (2016) Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer. Nanomed. Nanotechnol. Biol. Med. 12, 1853–1861, https://doi.org/10.1016/j.nano.2016.04.002
89 Basu, S., Harfouche, R., Soni, S., Chimote, G., Mashelkar, R.A. and Sengupta, S. (2009) Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl. Acad. Sci. 106, 7957–7961, https://doi.org/10.1073/pnas.0902857106
90 Harfouche, R., Basu, S., Soni, S., Hentschel, D.M., Mashelkar, R.A. and Sengupta, S. (2009) Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 12, 325, https://doi.org/10.1007/s10456-009-9154-4
91 Kulkarni, A.A., Roy, B., Rao, P.S., Wyant, G.A., Mahmoud, A., Ramachandran, M. et al. (2013) Supramolecular nanoparticles that target phosphoinositol-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res. 73, 6987–6997, https://doi.org/10.1158/0008-5472.CAN-12-4477
92 Pandey, A., Kulkarni, A., Roy, B., Goldman, A., Sarangi, S., Sengupta, P. et al. (2014) Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Res. 74, 675–685, https://doi.org/10.1158/0008-5472.CAN-13-3783
93 Hoffmann, F., Sass, G., Zilles, J., Zahler, S., Tiegs, G., Hartkorn, A. et al. (2009) A novel technique for selective NF-κB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia–reperfusion. Gut 58, 1670–1678, https://doi.org/10.1136/gut.2008.165647
94 Hattori, Y., Sakaguchi, M. and Maitani, Y. (2006) Folate-linked lipid-based nanoparticles deliver a NFκB decoy into activated murine macrophage-like RAW264. 7 cells. Biol. Pharm. Bull. 29, 1516–1520, https://doi.org/10.1248/bpb.29.1516
95 Xu, M.-X., Ge, C.-X., Li, Q., Lou, D.-S., Hu, L.-F., Sun, Y. et al. (2020) Fisetin nanoparticles protect against PM2.5 exposure-induced neuroinflammation by down-regulation of astrocytes activation related NFκB signaling pathway. J. Funct. Foods 65, 103716, https://doi.org/10.1016/j.jff.2019.103716
96 Gai, W., Hao, X., Zhao, J., Wang, L., Liu, J., Jiang, H. et al. (2020) Delivery of benzoylecystine using biodegradable nanoparticles to suppress inflammation via regulating NFκB signaling. Colloids Surf. B 191, 110980, https://doi.org/10.1016/j.colsurfb.2020.110980
97 Chen, Y.-P., Chen, C.-T., Liu, T.-P., Chien, F.-C., Wu, S.-H., Chen, P. et al. (2020) Catcher in the rel: nanoparticles-antibody conjugate as NFκB nuclear translocation blocker. Biomaterials 246, 119997, https://doi.org/10.1016/j.biomaterials.2020.119997
98 Abdel-Hakeem, E.A., Abdel-Hamid, H.A. and Abdel Hafez, S.M.N. (2020) The possible protective effect of Nano-Selenium on the endocrine and exocrine pancreatic functions in a rat model of acute pancreatitis. J. Trace Elem. Med. Biol. 60, 126480, https://doi.org/10.1016/j.jtemb.2020.126480
99 Xu, X., Rui, S., Chen, C., Zhang, G., Li, Z., Wang, J. et al. (2020) Protective effects of astragalus polysaccharide nanoparticles on septic cardiac dysfunction through inhibition of TLRA/NFκB signaling pathway. Int. J. Biol. Macromol. 153, 977–985, https://doi.org/10.1016/j.ijbiomac.2019.10.227
100 Sahab-Negah, S., Ariakia, F., Jalili-Nik, M., Afshari, A.R., Salehi, S., Samini, F. et al. (2020) Curcumin loaded in niosomal nanoparticles improved the anti-tumor effects of free curcumin on glioblastoma stem-like cells: an in vitro study. Mol. Neurobiol. 57, 3391–3411, https://doi.org/10.1007/s12035-020-01922-5
101 Ramirez, R., Matrama, M., Satti, S., Griffin, R., Voros, B., Mohammed, A. et al. (2019) EP1.12-18 NET-001: A Phase II Study of ABI-009 in Metastatic Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System. J. Thoracic Oncol. 14, https://doi.org/10.1016/j.jtho.2019.08.2263
102 Mumaeva, V., Rosenholm, J.M., Batte-Eya, L.T., Bergman, L., Peuhu, E., Duchanoy, A. et al. (2011) Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. 19, 1538–1546, https://doi.org/10.1038/mt.2011.105
103 Tsai, Y.S., Chen, Y.H., Cheng, P.C., Tsai, H.T., Shiau, A.L., Tsai, T.S. et al. (2013) TGF–β1 Conjugated to gold nanoparticles results in protein conformational changes and attenuates the biological function. Small 9, 2119–2128, https://doi.org/10.1002/smll.201202755
104 Verma, R.K., Yu, W., Wang, S.P., Shankar, S. and Srivastava, R.K. (2015) Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway. Nanomed. Nanotechnol. Biol. Med. 11, 2061–2070, https://doi.org/10.1016/j.nano.2015.07.001
105 Crombez, L., Morris, M.C., Dufort, S., Adiran-Herrada, G., Nguyen, Q., Mc Master, G. et al. (2009) Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour necrosis. Nucleic Acids Res. 37, 4559–4569, https://doi.org/10.1093/nar/gkp451
106 Kanazawa, T., Morisaki, K., Suzuki, S. and Takashima, Y. (2014) Prolongation of life in rats with malignant glioma by intranasal siRNA/drug co-delivery to the brain with cell-penetrating peptide-modified micelles. Mol. Pharm. 11, 1471–1478, https://doi.org/10.1021/mp400644a
107 Lee, S.H., Kim, S.H. and Park, T.G. (2007) Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 357, 511–516, https://doi.org/10.1016/j.bbrc.2007.03.185
108 Gayen, P., Sen, S., Chowdhury, N., Ghosh, S., Hembram, M., Bagchi, A. et al. (2021) Engineered bio-inspired multifunctional peptide-and protein-based therapeutic biomolecules for better wound care. Chemistry–An Asian J. 16, 4018–4036, https://doi.org/10.1002/asia.202101022
109 Ghosh, S., Gayen, P., Jan, S., Kishore, A.V., Kumar, V., Mallick, A.M. et al. (2020) Biospired non-immunogenic multifunctional sealant for efficient blood clotting and suture-free wound closure. ACS Biomaterials Sci. Eng. 6, 6378–6393, https://doi.org/10.1021/acsbiomaterials.0c01254
110 Ghosh, S., Mukherjee, S., Dutta, C., Chakraborty, K., Gayen, P., Jan, S. et al. (2017) Engineered isopeptide bond stabilized fibrin inspired nanoscale peptide based sealants for efficient blood clotting. Sci. Rep. 7, 1–13, https://doi.org/10.1038/s41598-017-06360-3
111 Nishida, N., Yano, H., Nishida, T., Kamura, T. and Kojiro, M. (2006) Angiogenesis in cancer. Vascular Health Risk Manage. 2, 213, https://doi.org/10.2147/vhrm.2006.2.3.213
113 Banerjee, D., Harfouche, R. and Sengupta, S. (2011) Nanotechnology-mediated targeting of tumor angiogenesis. Vascular Cell 3, 1–13, https://doi.org/10.1186/2045-824X-3-3
114 Kerbel, R.S. and Kamen, B.A. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423–436, https://doi.org/10.1038/nrc1369
115 Sengupta, S., Eavarone, D., Capilla, I., Zhao, G., Watson, N., Kızıltepe, T. et al. (2005) Temporal targeting of tumour cells and neovascularization with a nanoscale delivery system. Nature 436, 568–572, https://doi.org/10.1038/nature03794
116 Chaudhuri, P., Harfouche, R., Soni, S., Hentschel, D.M. and Sengupta, S. (2010) Shape effect of carbon nanovectors on angiogenesis. ACS Nano 4, 574–582, https://doi.org/10.1021/nn100146h
117 Satchi-Fainaro, R., Puder, M., Davies, J.W., Tran, H.T., Sampson, D.A., Greene, A.K. et al. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255–261, https://doi.org/10.1038/nm1002
118 Miller, K., Erez, R., Segal, E., Shabat, D. and Satchi-Fainaro, R. (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer–alendronate–taxane conjugate. Angew. Chem. 121, 2993–2998, https://doi.org/10.1002/ange.200805133
119 Mitra, A., Mulholland, J., Nan, A., McNeill, E., Ghaneharsi, H. and Line, B.R. (2005) Targeting tumor angiogenic vasculature using polymer–RGD conjugates. J. Control. Release 102, 191–201, https://doi.org/10.1016/j.jconrel.2004.09.023
120 Kim, W.J., Yockman, J.W., Jeong, J.H., Christensen, L.V., Lee, M., Kim, Y.-H. et al. (2006) Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J. Control. Release 114, 381–388, https://doi.org/10.1016/j.jconrel.2006.05.029
121 Schifferlers, R.M., Ansari, A., Xu, J., Zhou, G., Tang, Q., Storm, G. et al. (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149–e149, https://doi.org/10.1093/nar/gnh140
122 Pillé, J.-Y., Li, H., Blot, E., Bertrand, J.-R., Pritchard, L.-L., Opolon, P. et al. (2006) Intravenous delivery of anti-Rhα small interfering RNA loaded nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17, 1019–1026, https://doi.org/10.1089/hum.2006.17.1019
123 Backer, M.V., Gaynutdinov, T.I., Patel, V., Bandyopadhyaya, A.K., Thirumamagal, B., Tjarks, W. et al. (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 4, 1423–1429, https://doi.org/10.1158/1535-7163.MCT-05-0161
124 Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I. et al. (2008) An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 26, 799–807, https://doi.org/10.1038/nbt1415
125 Nasongkla, N., Shuai, X., Ai, H., Weinberg, B.D., Pink, J., Boothman, D.A. et al. (2004) cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem. 116, 6483–6487, https://doi.org/10.1002/ange.200406900
126 Maeda, N., Takeuchi, Y., Takada, M., Sadzuka, Y., Namba, Y. and Oku, N. (2004) Anti-angiogenic therapy by use of tumor neovascularization-targeted long-circulating liposome. J. Control. Release 106, 41–52, https://doi.org/10.1016/j.jconrel.2004.07.033
127 Villares, G.J., Zigler, M., Wang, H., Melnikova, V.O., Wu, H., Friedman, R. et al. (2006) Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 66, 9078–9086, https://doi.org/10.1158/0008-5472.CAN-06-2397
128 Chen, J., Wu, H., Han, D. and Xie, C. (2006) Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 231, 169–175, https://doi.org/10.1016/j.canlet.2005.01.024
129 Maeng, J.H., Lee, D.-H., Jung, K.H., Bae, Y.-H., Park, I.-S., Jeong, S. et al. (2010) Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 31, 4995–5006, https://doi.org/10.1016/j.biomaterials.2010.02.068
130 Cui, T., Liang, J.-J., Chen, H., Geng, D.-D., Jiao, L., Yang, J.-Y. et al. (2017) Performance of doxorubicin-conjugated gold nanoparticles: regulation of drug location. ACS Appl. Mater. Interfaces 9, 8569–8580, https://doi.org/10.1021/acsami.6b06669
131 Mirza, Z. and Karim, S. (2011) Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advances and future challenges. Seminars in cancer biology, pp. 226–237, Elsevier, https://doi.org/10.1016/j.semcancer.2010.04.020
132 Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dörkin, J.R. and Anderson, D.G. (2014) Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555, https://doi.org/10.1038/nrg3783
133 Wang, J., Kleveland, F.M. and Zhang, M. (2016) Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacol. Res. 114, 56–66, https://doi.org/10.1016/j.phrs.2016.10.016
134 Loney, C., Vandenbranden, M. and Ruyschaert, J.-M. (2008) Cationic liposomal lipids: from gene carriers to cell signaling. Prog. Lipid Res. 47, 340–347, https://doi.org/10.1016/j.plipres.2008.03.002
135 Kanasty, R., Dörkin, J.R., Vegas, A. and Anderson, D. (2013) Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967–977, https://doi.org/10.1038/nmat3765
136 Hou, X., Zaks, T., Langer, R. and Dong, Y. (2021) Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094, https://doi.org/10.1038/s41578-021-00358-0
137 Wang, X., Niu, D., Hu, C. and Li, P. (2015) Polyethyleneimine-based nanocarriers for gene delivery. Curr. Pharm. Des. 21, 6140–6156, https://doi.org/10.2174/1381612821666151027152907
138 Ekladious, I., Colson, Y.L. and Girnastoff, M.W. (2019) Polymer–drug conjugate therapeutics: advances, insights and prospects. Nat. Rev. Drug Discovery 18, 273–294, https://doi.org/10.1038/s41573-018-0005-0
139 Appelbaum, J.S., LaRochelle, J.R., Smith, B.A., Balkin, D.M., Holub, J.M. and Schepartz, A. (2012) Arginine topology controls escape of minimally cationic proteins from early endosomes to the cytoplasm. Chem. Biol. 19, 819–830, https://doi.org/10.1016/j.chembiol.2012.05.022
140 Mallick, A.M., Chakraborty, K., Biswas, A., Jan, S., Dutta, C., Dey, S. et al. (2019) Emerging peptide-based technologies in cancer therapy. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach, pp. 13–49, Springer, https://doi.org/10.1007/978-981-32-9816-3_2
141 Bulut, S., Erkal, T.S., Toksoz, S., Tekinay, A.B., Tekinay, T. and Guler, M.O. (2011) Slow release and delivery of antisense oligonucleotide drug by self-assembled peptide amphiphile nanofibers. *Biomacromolecules* **12**, 3007–3014, https://doi.org/10.1021/bm200641e

142 Muzzo, M., Hadjimemetrou, M., de Lazaro, I., Bussy, C. and Kostarelos, K. (2015) Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery. *ACS Nano* **9**, 1137–1149, https://doi.org/10.1021/nn5044838

143 Deshayes, S., Morris, M., Divita, G. and Heitz, F. (2005) Cell-penetrating peptides: tools for intracellular delivery of therapeutics. *Cell. Mol. Life Sci.* **62**, 1839–1849, https://doi.org/10.1007/s00018-005-5109-0

144 Deshayes, S., Gerbal-Chaalou, S., Morris, M.C., Aldrian-Herrada, G., Charnet, P., Divita, G. et al. (2004) On the mechanism of non-endosomal peptide-mediated cellular delivery of nucleic acids. *Biochimica et Biophysica Acta* **1667**, 141–147, https://doi.org/10.1016/j.bbamem.2004.09.010

145 Tarvirdipour, S., Huang, X., Mihali, V., Schonenberger, C.-A. and Pallivan, C.G. (2020) Peptide-based nanoassemblies in gene therapy and diagnosis: paving the way for clinical application. *Molecules* **25**, 3482, https://doi.org/10.3390/molecules25153482

146 Dizaj, S.M., Safari, S. and Khorosroukhahi, A.Y. (2014) A sight on the current nanoparticle-based gene delivery vectors. *Nanoscale Res. Lett.* **9**, 1–9, https://doi.org/10.1186/1556-276X-9-252

147 Pantarotto, D., Briand, J.-P., Prato, M. and Bianco, A. (2004) Translocation of bioactive peptides across cell membranes by carbon nanotubes. *Chem. Commun.* **16–17**, https://doi.org/10.1039/b311254c

148 Isobe, H., Nakanishi, W., Tomita, N., Jinno, S., Okayama, H. and Nakamura, E. (2006) Gene delivery by aminofullerenes: structural requirements for efficient transfection. *Chemistry–An Asian J.* **1**, 167–175, https://doi.org/10.1002/asia.200600051

149 Chen, Y., Chen, H. and Shi, J. (2014) Inorganic nanoparticle-based drug delivery systems to overcome the multidrug resistance of cancer cells. *Mol. Pharm.* **11**, 2495–2510, https://doi.org/10.1021/mp400596v

150 Hattab, D., Gazzali, A.M. and Bakhtiar, A. (2021) Clinical advances of siRNA-based nanotherapeutics for cancer treatment. *Pharmaceutics* **13**, 1009, https://doi.org/10.3390/pharmaceutics13071009

151 Hattab, D. and Bakhtiar, A. (2020) Bioengineered siRNA-based nanoparticles targeting molecular signaling pathways for the treatment of triple negative breast cancer: preclinical and clinical advancements. *Pharmaceutics* **12**, 929, https://doi.org/10.3390/pharmaceutics12100929

152 Salvioni, L., Zuppone, S., Andreata, F., Monieri, M., Mazzucchelli, S., Di Carlo, C. et al. (2020) Nanoparticle-mediated suicide gene therapy for triple negative breast cancer. *Adv. Therapeut.* **3**, 2000007, https://doi.org/10.1002/adtp.202000007

153 Choi, J., Rui, Y., Kim, J., Gorelick, N., Wilson, D.R., Kozielski, K. et al. (2020) Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. *Nanomed. Nanotechnol. Biol. Med.* **23**, 102115, https://doi.org/10.1016/j.nano.2019.102115

154 Conde, J., Tian, F., Hernandez, Y., Bao, C., Baptista, P.V., Cui, D. et al. (2015) RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing. *Nanose 7*, 9083–9091, https://doi.org/10.1039/C4NR05742B

155 Mutliah, M., Che, H.-L., Kalash, S., Jy, J., Choi, S.-Y., Kim, W.J. et al. (2015) Formulation of glutathione responsive anti-proliferative nanoparticles from thiolated Akt1 siRNA and disulfide-crosslinked PEI for efficient anti-cancer gene therapy. *Colloids Surf. B* **126**, 322–327, https://doi.org/10.1016/j.colsurfb.2014.12.022

156 Cohen, Z.R., Ramishetti, S., Peshes-Yaloz, N., Wolh, A., Zibly, Z. et al. (2015) Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. *ACS Nano* **9**, 1581–1591, https://doi.org/10.1021/nn50624B

157 Li, L., Wang, L., Wilcox, D., Sarthy, A., Lin, X., Huang, X. et al. (2013) Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach. *Mol. Cancer Ther.* **12**, 2308–2318, https://doi.org/10.1158/1535-7186.MCT-12-0963-T

158 Prencipe, F., Diaperia, C., Rossi, F., Roniga, L., Tesauro, D. et al. (2021) Forward Precision Medicine: Micelles for Active Targeting Driven by Peptides. *Adv. Therapeut.* **3**, 102115, https://doi.org/10.1002/adtp.202000007

159 Podesta, J.E., Al-Jamil, K.T., Herrero, M.A., Tian, B., Ali-Boucetta, H., Hegde, V. et al. (2009) Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. *Small* **5**, 1176–1185, https://doi.org/10.1002/smll.2008001572

160 Kara, G., Parlar, A., Cakmak, M.C., Cokol, M., Denkbas, E.B. and Bakan, F. (2020) Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy. *Colloids Surf. B* **196**, 111340, https://doi.org/10.1016/j.colsurfb.2020.111340

161 Ghosh, R., Singh, L.C., Shohet, J.M. and Gunaratne, P.H. (2013) A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. *Biomaterials* **34**, 807–816, https://doi.org/10.1016/j.biomaterials.2012.10.023

162 Devalupally, R., Sekar, N.M., Sekar, T.V., Foygel, K., Massoud, T.F., Willmann, J.K. et al. (2015) Polymer nanoparticles mediated codelivery of antimir-10b and antimir-21 for achieving triple negative breast cancer therapy. *ACS Nano* **9**, 2290–2302, https://doi.org/10.1021/nn507465d

163 Ebrahimian, M., Taghavi, S., Mokhtarzadeh, A., Ramezani, M. and Hashemi, M. (2017) Co-delivery of doxorubicin encapsulated PLGA nanoparticles and Bcl-xl shRNA using alkyl-modified PEI into breast cancer cells. *Appl. Biochem. Biotechnol.* **183**, 126–136, https://doi.org/10.1007/s12010-017-2434-3

164 Jiang, H.-L., Xu, C.-X., Kim, Y.-K., Arote, R., Jere, D., Lim, H.-T. et al. (2009) The suppression of lung tumorigenesis by aerosol-delivered folate–chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. *Biomaterials* **30**, 5844–5852, https://doi.org/10.1016/j.biomaterials.2009.07.017

165 Cole, G., Ali, A.A., McErlean, E., Muhillion, E.J., Short, A., McCrudden, C.M. et al. (2019) DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. *Acta Biomater.* **96**, 480–490, https://doi.org/10.1016/j.actbio.2019.07.003

166 Öberli, M.A., Reichmuth, A.M., Dorkin, J.R., Mitchell, M.J., Fenton, O.S., Jaklenec, A. et al. (2017) Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. *Nano Lett.* **17**, 1326–1335, https://doi.org/10.1021/acs.nanolett.6b03329

167 Bijnsdorp, I.V., Giovannetti, E. and Peters, G.J. (2011) Analysis of drug interactions. *Cancer cell culture*, pp. 421–434, Springer, https://doi.org/10.1007/978-1-61779-080-5_34
249 Chandra, P., Khandare, J.J., Ber, E., Rodriguez-Rodriguez, L. and Minko, T. (2010) Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharmacol. Res. 27, 2296–2306, https://doi.org/10.1007/s10955-010-0235-2

250 Lee, J.H., Sabnis, G., Brodie, A. and Nan, A. (2011) In vitro evaluation of HER2 targeted N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer conjugates in combination treatment with tyrosine kinase inhibitor (PKI-166). AACR 71, 3230

251 Lammers, T., Subr, V., Ulbrich, K., Peschke, P., Huber, P.E., Hennink, W.E. et al. (2009) Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototopic polymeric drug carriers. Biomaterials 30, 3466–3475, https://doi.org/10.1016/j.biomaterials.2009.02.040

252 Xu, Q., Leong, J., Chua, Q.Y., Chi, Y.T., Chow, P.K.-H., Pack, D.W. et al. (2013) Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 34, 5149–5162, https://doi.org/10.1016/j.biomaterials.2013.03.044

253 Lin, Y.-W., Raj, E.N., Liao, W.-S., Lin, J., Liu, K.-K., Chen, T.-H. et al. (2017) Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. Sci. Rep. 7, 1–11, https://doi.org/10.1038/s41598-017-09983-8

254 Thapa, R.K., Byeon, J.H., Choi, H.-G., Yong, C.S. and Kim, J.O. (2017) PEgylated lipid bilayer-wrapped nano-graphene oxides for synergistic co-delivery of doxorubicin and rapamycin to prevent drug resistance in cancers. Nanotechnology 28, 295101, https://doi.org/10.1088/1361-6528/aa7997

255 Nair, G.G. and Nair, C.K.K. (2014) Sanazole directed targeting of silver nanoparticle drug complex to tumor mass: A preclinical investigation in murine model. J. Cancer Res. Therapeut. 10, 979, https://doi.org/10.4103/0973-1482.148705

256 Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y. et al. (2018) Elimination of established tumors with nanodisc-based combination chemotherapy and immunotherapy. J. Gastrointestinal Liver Dis. 21, 187–196

257 Seth, A., Heo, M.B. and Lim, Y.T. (2014) Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for cancer immunotherapy. Biochem. Pharmacol. 97, 445–456, https://doi.org/10.1016/j.ijpharm.2013.08.010

258 Saruta, E.C., Huang, L., Chen, Y. and Tucker-Kellogg, L. (2018) Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer. Cancer Sci. 78, 724–730, https://doi.org/10.1038/s41591-018-0040-8

259 Malonis, R.J., Lai, J.R. and Vergnolle, O. (2019) Peptide-based vaccines: current progress and future challenges. J. Immunotherapy Cancer 7, 1181, https://doi.org/10.2217/fon-2017-0607

260 Roy, A., Singh, M.S., Upadhyay, P. and Bhaskar, S. (2013) Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int. J. Pharm. 404, 171–180, https://doi.org/10.1016/j.ijpharm.2013.01.045
303 Sanche, L. (2009) Beyond radical thinking. Nature 461, 358–359, https://doi.org/10.1038/461358a
304 Kachikwu, E.L., Iwamoto, K.S., Liao, Y.-P., DeMarco, J.J., Agazaryan, N., Economou, J.S. et al. (2011) Radiation enhances regulatory T cell representation. Int. J. Radiation Oncol.* Biol.* Physics 81, 1128–1135, https://doi.org/10.1016/j.ijrobp.2010.09.034
305 Ngiow, S.F., McArthur, G.A. and Smyth, M.J. (2015) Radiotherapy complements immune checkpoint blockade. Cancer Cell 27, 437–438, https://doi.org/10.1016/j.ccell.2015.03.015
306 Kulkarni, A., Chandrasekar, V., Natarajan, S.K., Ramesh, A., Pandey, P., Nirgud, J. et al. (2018) A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat. Biomed. Eng. 2, 589–599, https://doi.org/10.1038/s41551-018-0254-6
307 Shields, C.W., Evans, M.A., Wang, L.-L., Baugh, N., Iyer, S., Wu, D. et al. (2020) Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579, https://doi.org/10.1126/sciadv.aaz6579
308 McArthur, G.A. and Ribas, A. (2013) Targeting oncogenic drivers and the immune system in melanoma. J. Clin. Oncol. 31, 499–506, https://doi.org/10.1200/JCO.2012.45.5568
309 Atefi, M., Avramis, E., Lassen, A., Wong, D.J., Robert, L., Foulad, D. et al. (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 20, 3446–3457, https://doi.org/10.1158/1078-0432.CCR-13-2797
310 Li, H., Xiao, Y., Li, Q., Yao, J., Yuan, X., Zhang, Y. et al. (2021) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell 40, 36e9–52e9
311 Chatterjee, S., Azad, B.B. and Nimmagadda, S. (2014) The intricate role of CXCR4 in cancer. Adv. Cancer Res. 124, 31–82, https://doi.org/10.1016/B978-0-12-411638-2.00002-1
312 Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S. et al. (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. 110, 20212–20217, https://doi.org/10.1073/pnas.1320318110
313 Villanueva, L., Álvarez-Enrico, D. and Esteller, M. (2020) The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 41, 676–691, https://doi.org/10.1016/j.it.2020.06.002
314 Covre, A., Coral, S., Nicolay, H., Parisi, G., Fazio, C., Colizzi, F. et al. (2015) Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology 4, e1019978, https://doi.org/10.1080/2162402X.2015.1019978
315 Fang, H., Guo, Z., Chen, J., Lin, L., Hu, Y., Li, Y. et al. (2021) Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat. Commun. 12, 1–19, https://doi.org/10.1038/s41467-021-27078-x
316 Hegde, P.S. and Chen, D.S. (2020) Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35, https://doi.org/10.1016/j.immuni.2019.12.011
317 Bouchlaka, M.N. (2011) Cancer immunotherapy: limitations and potential strategies. Doctoral dissertation, http://hdl.handle.net/11714/3978
318 Huber, V., Campisani, C., Porcozzi, A., Ferro, S., Lugini, L. and Triulzi, T. (2017) Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars in cancer biology, pp. 74–89, Elsevier, et al. In, https://doi.org/10.1016/j.semcancer.2017.03.001
319 Huang, R.-Y., Francois, A., McGray, A.R., Miliotto, A. and Odunsi, K. (2017) Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6, e1249561, https://doi.org/10.1080/2162402X.2016.1249561
320 Murciano-Goroff, Y.R., Warner, A.B. and Wolchok, J.D. (2020) The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 30, 507–519, https://doi.org/10.1038/s41422-020-0337-2